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Abstract

Pamela L. Kubinski
POLY(N-ISOPROPYLACRYLAMIDE)-BASED SCAFFOLDS
FOR TISSUE ENGINEERING APPLICATIONS
2012/2013
Jennifer Vernengo, Ph.D.
Master of Science in Chemical Engineering

The primary goal of this work is to investigate the potential of poly(Nisopropylacrylamide)-based scaffolds in tissue engineering applications, specifically
spinal injury and nucleus pulposus replacement. Poly(N-isopropylacrylamide), denoted
PNIPAAm, is a synthetic polymer with hydrophilic properties at room temperature, but
above 32C the chains become hydrophobic and entangle to form physical crosslinks.
This thermoresponsive property enables PNIPAAm to be implanted as a free-flowing
solution at room temperature and collapse into a gel in physiological conditions.
However, as a homopolymer, the hydrophobicity of PNIPAAm in vivo causes the
hydrogel to expel water and exhibit inelastic properties that do not mimic those of natural
tissue.

These limitations have been previously addressed by copolymerizing NIPAAm monomer
with a synthetic hydrophilic polymer, such as polyethylene glycol, or PEG.
Incorporation of hydrophilic PEG chains enables the hydrogel to absorb more water,
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generating an elastic hydrogel with high water content. This copolymer is suitable for
spinal cord applications because the scaffold can fill irregularly shaped spinal cord
defects non-invasively and its mechanical properties can be easily tailored. In this work,
PNIPAAm-PEG is evaluated in vitro as a candidate scaffold for repair of the injured
spinal cord. Biocompatibility of the scaffold is characterized using two cell lines, human
embryonic kidney cells (HEK) and rat fibroblasts expressing green fluorescent protein
(RF-GFP). The cells were suspended in a 10 wt% PNIPAAm-PEG solution and cultured
at 37°C. The viability of HEK was assessed over 25 days using a qualitative dual
fluorescent stain to distinguish between live and dead cells, and a quantitative MTT cell
proliferation assay.

RF-GFP viability was assessed over 15 days in vitro using

fluorescence microscopy. Results from these studies suggest that PNIPAAm-PEG is
non-toxic to cells and should be evaluated further in vivo for treatment of spinal cord
injuries.

Although PNIPAAm-PEG copolymers have also been studied for nucleus pulposus
replacement in the intervertebral disc, a more suitable PNIPAAm-based copolymer
scaffold is proposed here. In this work, hydrogels composed of PNIPAAm and natural
chondroitin sulfate-A (CS) are studied. CS is a glycosaminoglycan naturally found in
connective tissue and cartilage that is negatively charged and degraded by chondroitinase
ABC enzymes.

Incorporating CS into PNIPAAm will create a three-dimensional

hydrated copolymer network with increased elasticity and biocompatibility. As before,
the thermoresponsive properties of PNIPAAm enable the copolymer to be injected noninvasively. In addition, the biodegradability of CS will enhance the porosity of the
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hydrogel and create interconnected pores that aid in tissue ingrowth, nutrient transport to
and waste products from cells within the network.

In this work, the swelling and

degradation behavior, and the mechanical properties of PNIPAAm-CS copolymers are
characterized. Preliminary cytocompatibility is also performed in vitro using human
mesenchymal stem cells. Results from these analyses indicate that PNIPAAm-CS has
potential as a scaffold to replace the damaged nucleus pulposus and recreate the
biomechanical function of the disc.
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Chapter 1
Introduction

1.1 Tissue Engineering
The purpose of tissue engineering is to functionally repair and regenerate human
tissues. In general, this is accomplished using three basic components: cells, bioactive
molecules such as drugs or growth factors, and a biomaterial support system or scaffold
(1). Although scaffold requirements vary based on application, a biomaterial must satisfy
several criteria to be suitable for general tissue engineering purposes. First and foremost,
the biomaterial must be biocompatible, which is defined as the ability of a material to
perform while inducing an appropriate host immune response (2). This applies not only
to the scaffold material, but also to any leachable components and degradation products.
Since scaffolds are typically used as carriers for cells, the scaffold should have sufficient
void space and pore interconnectivity to enable tissue ingrowth and transport of both
nutrients to the cells and waste products from the cells (1). Likewise, the scaffold should
be cytocompatible and promote cell proliferation and differentiation. It should also
possess appropriate mechanical properties and biodegradability.

For instance, the

mechanical properties should not only mimic that of the natural tissue of interest, but also
support the tissue in load bearing applications. In cases of biodegradable scaffolds, the
biomaterial should degrade at a rate that enables tissue regeneration while maintaining
mechanical integrity and necessary structural support (1).
Recently, the potential of injectable biomaterials as scaffolds in tissue engineering
has been realized. This approach enables the scaffold to be administered in a minimally
invasive manner that prevents further tissue damage to the target site.
1

Injectable

biomaterials that gel in situ can also take the shape of the tissue defect, eliminating the
need for patient-specific prefabrication. Suitable in situ gelling scaffolds must support a
suspended cell population prior to injection and during solidification; therefore, the
solidification process should occur under mild conditions to prevent cell death. These
concepts are applied in this work to investigate the potential of two injectable scaffolds
for spinal cord injury and repair of intervertebral disc degeneration.

2

Chapter 2
Background
2.1 Organization of the Nervous System
The nervous system is organized into the peripheral and central nervous systems,
which differ in both physiology and function. In the peripheral nervous system (PNS),
neurons receive information from the external environment and carry information
between the periphery and the central nervous system (CNS), which consists of the brain
and spinal cord (3, 4). Neurons, or nerve cells, are specialized electrically excitable cells
that receive and send signals to other cells through branched projections and extensions,
called dendrites and axons, as depicted in Figure 2.1 (4, 5). Neurons are interconnected
at synapses, throughout the nervous system, where an electrical impulse is sent from the
axon terminal and converted to a chemical signal, or neurotransmitter. The signal is then
passed to the dendrite of the next neuron, where it is received and converted back into an
electrical signal (4). Most neurons give rise to many dendrites, which receive and
transmit incoming synaptic information to the nerve cell body, and a single axon that
extends away from the cell body and conveys impulses from the neuron to its synaptic
terminal.

Each axon consists of a cylindrical tube of cytoplasm, in addition to

neurofilaments and microtubules that comprise the cytoskeleton and provide a framework
for fast axonal transport (5). Moreover, each axon is wrapped in concentric layers of
lipid-rich plasma membrane, referred to as myelin sheath, that serve to increase the speed
at which impulses are propagated along axons (6).
Functionally, neurons can be classified into three classes: afferent neurons,
efferent neurons, and interneurons (4). Afferent neurons are associated with the afferent
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division of the PNS and carry information from the external environment to the CNS; as
a result, afferent neurons lie primarily within the PNS, with axon terminals that project
into the spinal cord. Likewise, efferent neurons are associated with the efferent division
of the CNS and are responsible for transmitting instructions from the CNS to effector
organs, which respond to the instructions. Although efferent neurons also lie primarily in
the PNS, the cell bodies of these neurons originate in the CNS and the efferent axons
extend throughout the PNS. Afferent and efferent neurons are interconnected through
interneurons, which lie entirely within the CNS to integrate the peripheral responses to
peripheral information (4).

Approximately 99% of all neurons are interneurons.

However, only about 10% of cells within the CNS are neurons.
The vast majority of cells within the CNS are glial cells that support the
functionally important neurons. For instance, glial cells maintain the composition of the
extracellular environment surrounding neurons and actively modulate synaptic function
(4, 7). These cells include astrocytes, oligodendrocytes, microglia, and ependymal cells.
Astrocytes, the most abundant glial cells, maintain the proper spatial arrangements of
neurons, enhance synapse formation, modify synaptic transmission, and form neural scar
tissue, among other functions. Oligodendrocytes contribute to myelin sheath formation
around axons, while microglia serve as immune defense cells within the CNS. When not
activated, microglia release nerve growth factor to aid in neuronal and glial cell survival.
Ependymal cells line the internal, fluid filled cavities of the CNS (4). Unlike neurons,
which do not undergo cell division, glial cells maintain the ability to divide.
Nevertheless, glial cells are responsible for maintaining various physiological functions
and any damage to these cells will evidently dictate functional losses (8).
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2.2 Anatomy and Physiology of the Spinal Cord
The spinal cord is composed of nervous tissue, approximately 2 cm thick and 45
cm long, that connects the brain to all muscles of the body, as well as many sensory
nerves to the brain (4, 6). Hence, the spinal cord plays a central role in neuronal
signaling from external and internal stimuli (9). To perform this task, the spinal cord is
organized with a butterfly-shaped core of gray matter, surrounded by a ring of white
matter, as depicted in Figure 2.2. Each half of the gray matter can be further subdivided
into a dorsal, ventral, and lateral horn. The dorsal horn contains the cell bodies of
interneurons where afferent axonal fibers terminate, while the ventral horn contains
efferent neuronal cell bodies that provide motor input to skeletal muscles (4). Efferent
neuronal cell bodies that provide input to cardiac and smooth muscle and exocrine glands
are located in the lateral horn. Thus, the gray matter consists primarily of neuronal cell
bodies, dendrites, interneurons, and glial cells. The axonal extensions of the neuronal
cell bodies, clustered within the gray matter, branch throughout the white matter in
bundles. These bundles group to form ascending and descending tracts that transmit
signals between the PNS and CNS (4, 9). Afferent fibers, or axons carrying incoming
signals from the PNS, enter the spinal cord through the dorsal root; the cell bodies of
these neurons form clusters outside of the CNS referred to as dorsal root ganglion. Since
the cell bodies of efferent neurons cluster within the gray matter of the spinal cord, the
efferent fibers that carry outgoing signals from the CNS exit the spinal cord through the
ventral root (4, 6, 9). The dorsal and ventral roots at each level join and emerge from the
vertebral column to form a spinal nerve, a bundle of afferent and efferent peripheral
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neuronal axons. Each segment of the spinal cord gives rise to a pair of spinal nerves that
transverse between the spinal cord and a particular region of the body.

2.3 Anatomy of Vertebral Bodies
To protect this system, the spinal cord is surrounded by the vertebral column,
which consists of 33 cylindrical, interlocking vertebrae that are anatomically divided into
five regions: cervical, thoracic, lumbar, sacrum and coccyx (10). Of these regions, the
cervical spine represents the 7 vertebrae of the neck (C1 – C7), while the thoracic spine
represents the 12 vertebrae of the upper back (T1 – T2), which connect to 12 pairs of ribs;
the 5 vertebrae of the lower back comprise the lumbar spine (L1 – L5) and the spinal cord
usually finishes between the L1 and L2 vertebrae. The remaining 5 and 4 vertebrae
comprise the sacral and coccyx (tailbone) regions, respectively, in which the vertebrae
are fused and immobile. With the exceptions of these regions, and the C1 and C2
vertebrae of the cervical spine, the vertebral bodies are separated by intervertebral discs
that act as shock absorbers and provide mobility, load transfer, and energy dissipation to
the spine (10-12). In addition to the disc located anteriorly, two smaller facet joints are
located posteriorly between each vertebral body to guide spinal movement. Between the
disc and facet joints, the spinal nerves run down the spinal canal leaving the bony spine
through holes called intervertebral foramina.

2.4 Anatomy and Physiology of Intervertebral Discs
There are a total of 23 discs that separate the vertebral bodies. The discs are
approximately 4 cm in diameter and range from 7 – 10 mm in height, with the thickest
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discs located in the lumbar levels and the thinnest located at the cervical levels (13, 14).
The discs are strong, but deformable soft tissue that enables the upper vertebra to tilt in
all directions without contacting the lower vertebra (10). Biomechanically, the discs
must be strong enough to sustain weight, deformable to accommodate vertebral motion,
and strong enough to withstand movement. To accomplish this, intervertebral discs rely
on three basic components: a central nucleus pulposus, an outer annulus fibrosus, and
upper and lower vertebral endplates, as shown in Figure 2.3.
The nucleus pulposus is a semifluid cartilaginous mass of gel-like material,
containing a few cartilage cells (chondrocytes) and a network of irregularly arranged
collagen fibers interspersed through a proteoglycan medium (10, 15). It is approximately
70-90% water, which imparts it with fluid properties, while proteoglycans and collagen
comprise 65% and 15-20% of the dry weight, respectively (10, 16). Proteoglycans are
large molecules comprised of proteins linked to glycosaminoglycans (GAGs), which are
long chains of polysaccharides consisting of a repeated unit of a sugar molecule and a
sugar molecule with an amine group. GAGs predominantly found in the intervertebral
disc include chondroitin sulfate, keratin sulfate and hyaluronic acid; the cardinal
proteoglycan within the disc is aggrecan, although decorin and biglycan are also found in
small quantities (10). Proteoglycans not only bind water due to the ionic, carboxyl and
sulfate radicals associated with GAG chains, but also repair the disc matrix and, as a
result, are critical in maintaining homeostasis.

Chondrocytes, embedded within the

proteoglycan medium and located mainly near the vertebral endplate regions, are
responsible for synthesizing the constituents of the nucleus. As a fluid, the nucleus is
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incompressible and deforms under pressure, transmitting the applied pressure in all
directions.
Consequently, the annulus fibrosus is relatively stiff owing to its structure, which
enables it to resist buckling and oppose the outward pressure exerted by the nucleus. The
annulus is composed of sheets of collagen fibers, called lamellae, arranged in a highly
ordered pattern of concentric rings surrounding the nucleus (10). Within lamellae, the
fibers are oriented in parallel; however, among lamellae, the fibers are oriented in
alternating directions (10, 14, 16). Although the annulus is comprised of the same basic
components as the nucleus, the annulus is associated with substantially less water and
proteoglycan content. Only 20% of the dry weight is attributed to proteoglycans, while
50-60% is collagen. Additionally, elastin fibers represent about 10% of the annulus.
Together, the elastin enables the annulus to expand under applied pressure while the
tensile properties of collagen allow it to resist stretch and oppose the pressure exerted by
the nucleus. The annulus also contains chondrocytes and fibroblasts interspersed among
the collagen fibers, which attach the vertebral endplates to the disc.
The vertebral endplates are essentially two layers of cartilage that cover the top
and bottom aspects of each intervertebral disc and separate the disc from adjacent
vertebrae (10). Histologically, each endplate is 0.6 – 1 mm thick and consists of hyaline
cartilage and fibrocartilage, in addition to specialized capillaries used for nutrient
exchanged to the disc (10, 14, 16). Pockets of marrow cavity penetrate about 10% of the
surface area of the endplate to facilitate solute transport into and out of the disc via
diffusion. Consistent with the structure of the disc, the central region of the endplates
that covers the nucleus entirely contains a higher concentration of water and

8

proteoglycans, and a lower concentration of collagen (10). Likewise, the endplate region
over the annulus, which is not completely covered, is associated with lower
concentrations of water and proteoglycans, and a higher concentration of collagen.

2.4.1

Homeostasis of Intervertebral Discs
As mentioned previously, the proteoglycans and collagen associated with the

intervertebral disc are synthesized and maintained by chondrocytes and fibroblasts
located within the disc. Once synthesized, proteoglycans are delivered outside of the cell,
where proteoglycan aggregates form and bind to collagen fibers, forming the solid phase
of the matrix (10). The proteoglycans within the matrix bind to water, imparting the disc
with fluid properties. To maintain the properties of the disc, proteoglycans and collagen
are continuously degraded and replaced with new constituents. This turnover requires the
cells within the disc to be metabolically active; however, the disc is an avascular structure
that lacks a blood supply. As a result, the cells rely on diffusion for nutrients and
anaerobic metabolism, due to the low oxygen content within the disc. Furthermore, the
anaerobic metabolism of the cells results in lactic acid production, creating an acidic
environment with a pH of 6.9 – 7.1. Although the cells within the nucleus are most
active in a pH range of 6.9 – 7.2, activity is significantly compromised when the pH
drops below 6.8. Therefore, the matrix of the disc relies on a critical balance between the
synthetic and degradative activities of its cells (10).
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2.4.2

Functions and Biomechanics of Intervertebral Discs
Functionally, the intervertebral disc serves as a weight-bearing structure that

transmits loads among vertebral bodies and allows movement between the vertebrae (10).
The relatively stiff nature of the annulus, due to its densely packed collagen lamellae,
enables it to resist buckling and sustain weight. It has been experimentally demonstrated
that a disc with the nucleus removed can sustain the same axial load-bearing capacity as
an intact disc; this phenomenon demonstrates that the annulus can sufficiently transmit
briefly applied loads from one vertebra to the next, independent of the nucleus (10).
However, if subjected to prolonged weight-bearing, the sustained pressure will cause the
collagen lamellae to buckle, deforming the annulus. To prevent this liability, the nucleus
acts as an additional bracing mechanism to aid in weight-bearing. The nucleus acts as an
incompressible fluid that, under applied weight, rapidly expands outwards and exerts
pressure on the annulus. Subsequently, the collagen lamellae of the annulus stretch
outwards, but the tensile properties of collagen enable the lamellae to resist this stretch
and oppose the outward pressure exerted by the nucleus. Consequently, the nucleus
exerts pressure on the vertebral endplates, which resist deformation because the endplates
are applied to vertebral bodies. During compression under a 100 kPa load, approximately
8% of the water in the nucleus and 11% of the water in the annulus is expelled (10). As a
result, the concentration of electrolytes within the disc increases. After the compression
is released, this concentration gradient enables the disc to imbibe water and the balance is
restored.
In addition to the weight-bearing function of the disc, the intervertebral discs
provide motility to the spine.

For instance, the vertebral bodies can move in any
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direction if unrestricted. The vertebral bodies work in conjunction with the annulus to
perform distraction, sliding, rocking, bending, and twisting movements (10).

The

annulus acts both structurally and functionally like a ligament to restrain movement and
stabilize the joint.

2.5 Spinal Cord Injury
Second to stroke, spinal cord injury (SCI) is the leading cause of paralysis in the
United States, with an estimated annual incidence of 12,000 new cases each year (17, 18).
In 2010, approximately 265,000 people were reported to be living with SCI in the United
States, with over 80% of injuries occurring among males. An increase in the median age
of the general United States population has recently led to an increased age at the time of
injury, which averages 40.7 years (17). Over the last five years, SCI has predominantly
resulted from motor vehicle accidents, accounting for over 40% of all cases. Other
common etiologies of SCI include falls and violence, which represent nearly 28% and
15% of all cases, respectively.
The majority of SCIs, although heterogeneous, are the result of lacerations and
compression of the spinal cord, which represent 27% and 73% of all cases, respectively
(19). Lacerations are generally caused by penetrating objects that tear the spinal tissue
resulting in cord discontinuity, a phenomenon referred to as an ‘open’ injury. On the
other hand, compression of the spinal cord frequently leaves the cord intact, which is
referred to as a ‘closed’ injury, and can be subdivided into three types: massive
compression, contusion, and solid cord injury (6, 19). Neurologically, spinal cord injured
patients either sustain injuries to one of the eight cervical segments of the spinal cord,
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described by tetraplegia, or have lesions in the thoracic, lumbar, or sacral regions of the
spinal cord, described by paraplegia (17). Although SCIs are not restricted to a specific
spinal region, injuries are commonly sustained where the spine is most flexible, which
involves the C5 – C7 regions in the neck and the T10 – L2 regions in the lower back (19,
20). At the time of discharge, 39.5% of patients with SCI have incomplete tetraplegia,
22.1% have complete paraplegia, 21.7% have incomplete paraplegia, and 16.3% suffer
from complete tetraplegia
Based on the severity of the injury, the cost of health care and living expenses for
the first year following the injury ranges from $321,720 to $985,774. As a result, a
patient injured at age 25 has estimated lifetime costs ranging from $1,461,255 to
$4,373,912, while those injured at age 50 incur lifetime costs ranging from $1,031,394 to
$2,403,828 (17). In addition to these expenses, SCI victims also incur indirect costs.
These lifetime costs create a financial burden not only on those suffering from spinal cord
injuries, but also on the healthcare system. Aside from the economic impact of SCI,
injuries to the spinal cord are debilitating and generally irreversible, frequently causing a
reduced quality of life. Although life expectancies of SCI victims are steadily increasing,
there is no universal treatment currently available. Difficulty in treating SCI is largely
due to the hostile environment created by the cascade of events following injury.

2.5.1

Pathophysiology of SCI
Chronologically, injury to the spinal cord involves two distinct mechanisms of

primary and secondary injuries (8, 21, 22). The primary injury encompasses the initial
physical insult to the cord, usually resulting from dislocation of the vertebrae or displaced
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bone fragments, which triggers a local and systemic cascade of events that ultimately
cause secondary injury (8, 21). Secondary injury can be further subdivided into acute,
intermediate and chronic phases, and involves disruption of spinal cord blood flow,
peroxidation and membrane decomposition, free radical generation, release of
excitotoxins, inflammation and other phenomenon (8, 15).

This cascade of events

essentially destroys the spinal cord from the inside out, leaving behind a donut-shaped
area of white matter. Gray matter is completely lost at both the injury level and levels in
close proximity, which reduces the peripheral output of the spinal cord at the injury level
(9). In the event that white matter is damaged, function at all levels below the injury site
is eliminated.

2.5.1.1 Primary Injury Events
During primary injury, impact or trauma to the spinal cord causes physical
disruption to neural tissue and vasculature, which is commonly characterized by
vasodilation, congestion, and hemorrhaging (15, 23, 24). Locally, mechanical forces
applied at the injury site cause cell death, or necrosis, of neurons and endothelial cells
lining the blood vessels of the spinal cord (6, 22). Neuron necrosis is predominantly
localized to the more vascularized, soft gray matter that contains the cell bodies of
neurons.

However, within hours of the injury, a host of complex parallel

pathophysiological processes are initiated that contribute to secondary injury.
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2.5.1.2 Secondary Injury Events
The secondary, acute phase of SCI occurs for 1 – 2 days (15) post-injury and
consists of necrosis, hemorrhage, edema, inflammation, and neuronal and myelin changes
(15, 23). In response to the neuronal necrosis resulting from the initial impact, surviving
neurons fire a series of electrical impulses, or action potentials, causing local electrolytic
shifts and accumulation of neurotransmitters in neuron synapses.

Ultimately, these

events amplify the local necrosis of neurons and subsequent spinal shock, or failure of the
spinal cord to function, 2 – 24 h post-injury (6, 22, 23). In addition, endothelial cell
necrosis and vasculature rupture cause hemorrhaging of the spinal cord blood vessels and
disrupts the blood-spinal cord barrier that normally offers protection to the CNS.
Hemorrhaging into the normally fluid-filled space of the spinal cord consequently leads
to local swelling, or vasogenic edema, within the vertebral canal and impingement on
nearby neurons. Local blood vessels undergo vasospasm, causing a drastic reduction in
blood flow, and small-vessel thrombosis. These vascular changes result in ischemia,
depriving the cells of oxygen and nutrients, which further exacerbates necrosis. In
addition to vasogenic edema resulting from breakdown of the blood-spinal cord barrier,
cytotoxic edema characterized by intracellular swelling of astrocytes may occur. Edema,
in general, can also lead to vertebral displacement and compression of the spinal cord,
intensifying the injury (23).
Characteristic to the acute phase of injury is the presence of axonal swelling,
attributed to axonal degeneration, as well as inflammation (6, 15). Axons in the white
matter are severely injured during trauma and drive an initial inward leakage of sodium.
In an attempt to counteract this influx, sodium-calcium exchangers import damaging
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levels of calcium. An influx of calcium into CNS cells triggers the formation of free
radicals, which can induce cell death, and activates damaging enzymes and destructive
processes. SCI also results in swelling of myelin sheaths, which inevitably leads to
myelin breakdown and fragmentation (15). Concurrently, the immune system responds
to the injury in a cascade that results in inflammation and exacerbates secondary tissue
damage (6, 7, 22). Within an hour after injury, endothelial cells lining the spinal cord
blood vessels up-regulate cell adhesion molecules to activate and recruit neutrophils.
Neutrophils are white blood cells that perform several functions to impede invasion of
foreign invaders and aid in wound healing. A primary role of neutrophils includes
phagocytosis of foreign matter and tissue debris. However, these cells also exhibit a
respiratory burst that leads to the formation of free radicals and strong oxidizers in the
intracellular space, which can be released to kill foreign organisms but may cause local
tissue damage (2, 6).
During the intermediate phase of secondary injury, which takes place over a
period of days to weeks after the initial insult, the inflammatory cascade is propagated
and results in glial responses, elimination of necrotic debris and tissue revascularization
associated with restoration of the blood-spinal cord barrier. Neutrophils release cytokines
that activate and recruit other inflammatory and glial cells, and serve as a point of
communication between various cells of the immune response. Approximately 5 – 6 h
after the inflammatory response initiates, monocytes penetrate the spinal cord tissue from
the circulatory system and begin to differentiate into macrophages (2, 6). Although
functionally similar to neutrophils, macrophages have a higher capacity of phagocytosis
and remain at the injury site for a longer period of time.
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In addition to recruited

macrophages, microglia residing with the spinal cord become activated and aid in
phagocytosis and secretion of cytokines, free radicals and growth factors.

Since

cytokines and free radicals support expansion of the lesion site, the presence of growth
factors is critical for neuron survival and repair of the tissue. These macrophages and
microglia remain active over several weeks in order to remove necrotic debris and
minimize oxidative stress by free radicals within the CNS (2, 6, 15). Several days after
injury, astrocytes surrounding the lesion site continue to swell, reaching a peak of
hypertrophy between 2 – 3 weeks. Shortly thereafter, reactive astrocytes begin to form a
dense network of plasma membrane extensions to fill the empty lesion site, and form
glial scar that isolates the lesion from the remaining viable tissue during the final events
of secondary injury. These cells may also play a role in neurological recovery via uptake
of neurotransmitters, release of neuromodulators and growth factors, detoxification, free
radical scavenging and nutrient provision (15).
The last phase of SCI is the chronic or late phase of secondary injury, which
ensues weeks to months post-trauma.

Cell death begins to shift from necrotic to

apoptotic pathways, primarily afflicting oligodendrocytes (6, 15, 22). Apoptosis occurs
initially at the lesion site 6 h post-injury; after 1 week, a localized wave of apoptosis
occurs distances away from the primary injury site in the white matter. In particular, the
death of oligodendrocytes has an amplifying effect on the spinal cord.

Each

oligodendrocyte myelinates 10 – 40 axons; as a result, the death of a single cell can
inhibit the conduction capacity of many neurons, preventing communication between the
brain and body (6). As the lesion site becomes devoid of normal tissue, it begins to form
a fluid-filled cavity that can extend segments above and below the primary injury site,
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creating a physical gap that blocks axonal growth, as shown in Figure 2.4. Regeneration
is also inhibited by the formation of glial scar and deposition of inhibitory molecules by
oligodendrocytes, microglia and astrocytes. Astrocytes also up-regulate proteoglycans,
which directly inhibit axon growth. In addition to glial scarring, the spinal cord may be
replaced by fibrous connective tissue and collagen forming an impenetrable scar tissue
that further impedes axonal regeneration (15).

2.5.1.3 Challenges of Axonal Regeneration
Historically, it was believed that axons in the CNS were incapable of
regeneration; recently, however, experimental evidence indicates that axons have an
intrinsic capacity for regrowth until re-entering the CNS environment, demonstrating the
non-conducive nature of the CNS.

After trauma to neurons, axon extensions are

interrupted and undergo a process of acute axonal degeneration.

These extensions

experience an immediate calcium influx from the extracellular space that signals sealing
of the severed end (25, 26). In turn, calcium-dependent proteases are activated and
cleave target proteins, which can impair axonal transport. Increased calcium levels
within the axon can also induce autophagy, or degradation of the organelles and proteins
within the axon. Within 30 min of lesion, axonal neurofilaments become misaligned and
the microtubules are disrupted (25). As a result of dysfunctional axonal transport, the
organelles of the axons begin to accumulate locally and the axon swells. The increased
calcium levels within the axon induce autophagy, or degradation of the organelles and
proteins within the axon, and subsequent fragmentation of the axon extension over 400
µm proximal and distal from the injury site (25-27).
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Consequently, acute axonal

degeneration causes any side branch within 200 µm from the lesion site to disconnect
from the cell body, creating a gap that can significantly impede regeneration (27).
Axons distal to the lesion site, which are detached from the cell body, that are not
affected by acute axonal degeneration undergo a similar process of progressive depletion
referred to as Wallerian degeneration (6, 25-28). However, it is not the physical trauma
to the spinal cord that causes disintegration of these distal axons; in fact, the initial injury
typically leaves these axons in a macroscopically stable state (25). As detailed above,
this is not the case on the microscopic level, which inevitably results in axonal
fragmentation. Several days following injury, axonal membranes distal to the lesion site
exhibit beading and swelling, proceeded by disassembly of the axonal cytoskeleton,
which results in fragmentation or granular disintegration of the axon and its associated
myelin (22, 26, 27). The remnants and debris are phagocytosed by macrophages and
activated microglia (27, 29). Ultimately, this process leads to the complete removal of
axons distal to the lesion.
Axons proximal to the lesion, which are attached to the cell body, later undergo a
process of regenerative sprouting.

Macrophages and activated microglia change

phenotype and become actively involved in tissue repair and axonal sprouting (29). For
instance, microglia near the lesion express neurotrophic factors, which guide sprouting
axons.

Within days after injury, a degree of remyelination can occur by either

oligodendrocyte precursor cells or Schwann cells, which are myelinating cells found
within the peripheral nervous system that migrate into the spinal cord after injury (6). In
an effort to form new synapses and attain functional recovery, axon regrowth and
sprouting of new branches occurs from the tips of axons proximal to the lesion.
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However, upon reaching the primary lesion site sprouting is aborted and the axons form
dystrophic endbulbs representative of stalled growth (30). In addition to dystrophy, these
axonal growth cones can undergo collapse, a process by which axon growth post-injury is
stalled from membrane-membrane contact with mature oligodendrocytes and myelin
products.

The growth cone arrests, collapses and often retracts.

Despite these

observations, it is proposed that these axons maintain the ability to regenerate but are
inhibited by the hostile environment of the CNS, created after SCI (7, 31).
Several factors have been implicated as barriers to CNS axon extension. For
instance, when the remnants of the acute phase of injury, including myelin debris and
damaged axons, accumulate at the injury site, glial cells are recruited to the lesion (6).
As a result, extracellular matrix molecules are upregulated, such as chondroitin sulfate
proteoglycans, which directly inhibit axon growth and are potent inhibitors of growthpromoting molecules (6, 7, 30). These events cause glial scar formation, or reactive
gliosis, which acts perhaps as both a physical and molecular barrier to axon regeneration.
In addition, during the acute phase of injury, oligodendrocytes that myelinate the CNS
axons produce myelin-associated inhibitor molecules which make direct contact with the
axons and deter growth (22, 32). Moreover, neuron aging is likely correlated with
changes in expression and repression of genes, which ultimately reduce the ability of a
mature neuron to divide following injury (6, 29). In other words, even in the absence of
these inhibitors, adult neurons within the CNS lack an intrinsic potential to grow. Hence,
any recovery of function that occurs post-injury is largely due to the plasticity of the
surviving neurons. Based on this precedence, much research has been driven towards
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creating a microenvironment that is supportive of axon regeneration, such as “bridging”
the lesion site with growth facilitating cells and materials.

2.5.2

Treatment of SCI
Currently, there is no cure or standard clinical treatment available for patients

with SCI. However, neuroprotective strategies aimed at enhancing cell survival during
secondary injury are becoming more widespread.

In particular, administration of

methylprednisolone within 8 h post-injury is widely considered the “gold standard”
treatment, which is a corticosteroid proposed to inhibit lipid peroxidation and reduce
degenerative changes during secondary injury (33, 34). Nevertheless, the efficacy of
methylprednisolone is still controversial and it is not recommended for use in acute SCI
by the Food and Drug Administration (FDA) (7, 8, 34-37). Several other neuroprotective
pharmacologic agents have also been investigated in human clinical trials but, in general,
these agents have yet to exhibit a statistically significant clinical benefit that justifies use
(8, 38). Although therapies are not yet available that enable complete functional recovery
in patients suffering from SCI, function may be recovered to a degree through physical
training and the use of neuroprostheses (6, 23).
Due to the plasticity of the nervous system, it may be possible to partially recover
motor functions lost as a result of SCI. Physical therapy, such as body weight support
training, can be used to train and assist patients in locomotion in a way that prevents
overcompensation with spared motor functions and enables the nervous system to adapt
(6). In this manner, it may be possible to train the nervous system to adapt and relearn
rhythmic movements (6, 23, 29). In addition, a number of approaches using external
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devices or stimulation have been developed to facilitate movement during therapy and
artificially improve muscle function, such as robotic devices and functional electrical
stimulation (FES) (6, 8, 23, 38). FES uses a control unit and stimulating electrodes,
either taped to the patient’s skin or implanted near nerves innervating the desired muscle
groups, to provide mild shocks to the muscles. These shocks cause muscle contraction
that help maintain muscle mass and can initiate movement. As a result, FES can be used
to improve cardiovascular conditioning, gait control and speed, restore respiration, and
control bowel and bladder function (6, 8). However, FES is associated with considerable
drawbacks, such as the need for surgical intervention and, in some cases, it is required to
transect healthy sensory nerves entering the spinal cord (6).

2.5.2.1 Experimental Approaches
Despite the current lack of available therapies, numerous experimental strategies
are emerging that aim to reduce the effects of secondary injury, repair the spinal cord and
restore functionality.

In general, these approaches use pharmacologic treatments,

biologic agents, cell replacement therapies, transplants and/or biomaterials that target
specific destructive effects of SCI to provide neuroprotection and stimulate regeneration.
For example, researchers have investigated the use of steroids to reduce edema
and free radical production during acute SCI (7, 23). Alternatively, neuroprotective
agents have been used to target the excitotoxicity cascade that causes electrolyte shifts,
neurotransmitter accumulation and ultimately enhances necrosis. Such agents include
glutamate receptor antagonists, voltage-gated sodium channel blockers, and voltage-gated
potassium channel blockers, which interfere with the excitation of neurons (6, 23). Other
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researchers have investigated the effects of inhibiting inflammation through antiinflammatory agents, including the anti-angiogenic compound, CM101, used to prevent
inflammatory angiogenesis and inhibit glial scar formation; anti-inflammatory cytokines,
such as IL-10; and cyclooxygenase, or COX-2, inhibitors (23). Inflammation has also
been inhibited by temperature control via whole body hypothermia or local spinal cord
cooling, which can provide neuroprotective effects, improve recovery of sensory and
motor functions, and reduce mortality rates (8, 38). Attempts to prevent apoptosis of
neuronal and glial cells have also been made by inhibiting caspase proteases that aid in
mediating cell apoptosis, and calpain proteases that lead to cytoskeleton degradation of
damaged cells (6, 23, 25). Similarly, exogenous neurotrophins, such as glial-derived and
brain-derived neurotrophic factors, have been used to provide support to cells, which is
otherwise interrupted by injury (21, 23, 25, 32).
In addition to the above neuroprotective strategies that target the earlier stages of
SCI, much effort has been devoted to removing the barriers to axon regrowth during the
chronic stages of injury.

One approach aims to enhance the hostile extracellular

environment of the lesion using matrix proteins and growth factors, as well as genetic
deletion and pharmacological agents that target inhibitory signals of axonal growth, like
chondroitin sulfate proteoglycans (7, 23, 28, 30, 32, 38).

Endogenous activated

macrophages may also be used to scavenge degenerating myelin debris containing
inhibitory factors, and facilitate axon regeneration (8, 23, 32, 38). Due to the importance
of myelin in neuronal signal transmission, researchers are also investigating methods to
repair demyelination and impulse conduction.

As mentioned earlier, pharmacologic

agents that alter voltage-gated channel activity are currently being investigated, which
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may be used in this case to overcome conduction deficits (6). Another approach involves
the transplantation of cells that are capable of producing myelin, such as
oligodendrocytes, Schwann cells and olfactory ensheathing cells (OECs), into
demyelinated lesions (6, 32).

However, cell-based therapies are not limited to this

application. In addition to myelination, Schwann cells and OECs can also stimulate
axonal growth. Intriguingly, OECs can form channels that guide axons during growth, an
important aspect of achieving functional recovery, although OECs are not as readily
accessible as Schwann cells and do not readily expand in large numbers (6).
An attractive alternative to cell therapy with Schwann cells and OECs is the use
of stem cells, which can self-renew and mature into one or more specialized cell types
(6). Neural stem cells, in particular, are commonly studied adult stem cells for the
treatment of SCI because these cells can be isolated and have the ability to mature into
neurons or glial cells (6). Other stem cells of interest are mesenchymal cells, bone
marrow stromal cells, human embryonic stem cells and stem cells derived from tissue
surrounding the heart (6, 38). Regardless of cell type, the overall goal of this method is
to rescue, replace or provide a regenerative pathway for neurons that promotes proper
regeneration of spinal cord circuitry and restores function (23).

A similar

neuroregenerative approach involves the use of gene therapy to provide the injured spinal
cord with the necessary gene products, or proteins, needed for functional recovery (6, 7).
This process allows specific genes and controlled doses to be introduced to the injury
site, which is critical in order to maintain homeostasis during regeneration.
Despite the promising future of these experimental strategies, current data
surrounding these approaches must be interpreted with caution as experiments have been
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mostly confined to animal models; indeed, therapeutic strategies that have been tested
clinically have shown modest functional improvement, at best (38). Perhaps the most
promising approach to regeneration has been to bridge the lesion site with growthfacilitating cells and materials, a combination of therapeutic strategies, which will be
discussed in detail in the following section (29).

2.5.2.2 Tissue Engineering of the Spinal Cord
Based on the observation that nerve regeneration can occur within the peripheral
nervous system but PNS neurons fail to grow neurites into CNS tissue, it is postulated
that the lack of axonal regeneration within the CNS is not an intrinsic property of CNS
neurons, which readily regenerate processes into PNS tissue; rather, CNS tissue displays
non-permissive properties that impede axonal regrowth (31). For instance, the formation
of glial scar at the lesion site creates a molecular barrier to regeneration, while the
presence of neurite growth inhibitory prevents regrowth of these extensions following
injury. Consequently, it is conceivable that axons in the CNS will regenerate after injury
if a favorable microenvironment is designed that can bridge the lesion and physically
guide regenerating axons (7, 29). To this end, nerve grafts and polymeric conduits have
been used to bridge the gap in the injured spinal cord and repair damaged nerves.
Nerve grafting can be achieved using an autograft, in which nerve segments from
another part of the patient’s body are transplanted into the lesion site; an allograft, which
originates from another individual; or a xenograft, which originates from a different
species (19). Although autografts are biocompatible, generally non-toxic and provide a
support structure to promote cell adhesion and migration, this approach has many
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disadvantages. For example, autografts require a second surgical step, in which one or
more functioning nerves are sacrificed, there is a limited supply of donor nerves, and the
dimensions between the nerve and graft may not match appropriately. Despite that
allogenic and xenogenic nerve grafts overcome these pitfalls, tissues harvested from
another patient or species are associated with risks of disease transmission and
immunogenic response, which may ultimately result in tissue rejection (19).
Alternatively, tissue engineering represents a practical tool, which can be used to
generate conduits that provide a microenvironment permissive to the regeneration and
functional recovery of axons.

For instance, engineered scaffolds can be used to

physically guide sprouting axons, reduce scar tissue infiltration into the injury site,
promote cell adhesion and migration, and concentrate neurotrophic factors released from
injured nerve stumps (19, 32, 39). Currently, there is no effective scaffold clinically
available for use in the CNS; however, many natural and synthetic materials have been
investigated in both acellular and cellular scaffold approaches for SCI repair (19, 39-42).
Bakshi and colleagues (2004) investigated the use of poly(2-hydroxyethylmethacrylate)
(PHEMA) grafted with poly(ethylene glycol), a non-biodegradable hydrogel, as a
scaffold to treat SCI. The acellular conduit was engineered to exhibit a compressive
modulus analogous with in vivo spinal cord tissue, between 3 to 5 kPa, and displayed a
network with interconnected pores. In addition, in vivo implantation in a rodent model of
SCI revealed that PHEMA elicited a modest inflammatory response with minimal scar
formation; the scaffold also supported angiogenesis and, in the presence of BDNF,
induced axonal growth (43). In a later study, positively charged HEMA based hydrogels
were characterized in vivo for SCI repair following both acute and delayed implantation
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(40). Similar to observations from previous work, the HEMA hydrogel implants bridged
the cavity and supported the ingrowth of regenerating axons, with more effective repair
observed by delayed implantation. Despite these findings, PHEMA and HEMA-based
hydrogels require invasive procedures for implantation and must be pre-fabricated to
conform to the patient-specific lesion shape and size.
In other work, hyaluronan glycosaminoglycan was functionalized with thiol
groups and crosslinked using poly(ethylene glycol) diacrylate (44), resulting in an
injectable, biocompatible hyaluronic acid (HA) based hydrogel.

The ability of the

hydrogel to promote neurite outgrowth was demonstrated in vitro by polymerizing
thiolated HA in the presence of embryonic chick dorsal root ganglion explants and
incubating the culture over 8 days; neurites extended within the hydrogel as fine, intact,
uniform arrays over the culture period.

However, implantation of the HA based

hydrogels in a rodent model of SCI resulted in a profound inflammatory response that
rapidly degraded the conduit, and neither functional nor histological recovery of the
spinal cord was observed (44). Baumann and colleagues (2009) also investigated the
potential of hyaluronan for application in SCI repairs by dispersing it within a methyl
cellulose solution to generate an injectable HAMC hydrogel blend. The ability of the
hydrogel to serve as a drug delivery platform was assessed using a variety of
neuroprotective molecules that were either loaded directly within the hydrogel or within
poly(lactide-co-glycolide) (PLGA) particles dispersed throughout the HAMC blend.
From this work, it was observed that blends containing less HA were more stable over 28
days in vitro, and the stability of the blends was enhanced by the incorporation of
polystyrene model particles (33). The particle loaded HAMC blends also demonstrated
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extended drug release, and retained a high particle load.

Nevertheless, the safety,

mechanical properties, and degradation behavior were not characterized in this study and
in vivo evaluation is needed.
In another attempt to develop an injectable, biodegradable scaffold for injured
CNS tissue, Yasuda and colleagues (2010) investigated the effects of fibrin, a protein
involved in blood clotting, on bone marrow stromal cells. Fibrin matrix was prepared
from fibrinogen, blood coagulation factor XIII, plasmin inhibitor bovine aprotinin,
thrombin and calcium chloride, and the concentrations of fibrinogen and calcium chloride
were manipulated to achieve a clotting time that enabled the matrix to be injected, while
maintaining a suitable microstructure (45). The matrix was assessed in a rodent model of
cortical injury, in the presence and absence of bone marrow stromal cells, and compared
to transplantation of cells alone.

Of these groups, cell retention, proliferation,

differentiation, and migration into the lesion site was apparent only with the matrix-cell
suspension, suggesting a need for scaffolds in treating such injuries.
Perhaps a more suitable approach to preparing an injectable scaffold is to use
materials with stimuli-responsive properties, such as those that respond to changes in
temperature. For example, agarose scaffolds gel in situ and have been shown to support
neurite extension in a rodent model of SCI (46). Moreover, Jain and colleagues (2006)
demonstrated that agarose hydrogels are space filling and remain in the lesion, and can be
used to deliver brain-derived neurotrophic factor, which was shown to facilitate axonal
infiltration into the scaffold. The major caveat to the agarose scaffolds use in this study
is that gelation occurs at 17°C, requiring the use of a cooling system to achieve in situ
gelling.

Alternatively, Nisbet and colleagues (2008) assessed xyloglucan based
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hydrogels as scaffolds for SCI repair based on the thermoresponsive properties of the
polysaccharide, which can be exploited by partially removing the galactose groups from
the chains. In doing so, hydrophobic associations are formed and thermal gelation at
37°C can be achieved (42). Xyloglucan hydrogels exhibited elastic moduli comparable
to spinal cord tissue, and supported the growth and differentiation of primary cortical
neurons.

In addition, by functionalizing the hydrogels with poly-D-lysine, the cell

number, migration and neurite density could be controlled in vitro (42).
Although biodegradable scaffolds are common designs for SCI repair, these
materials offer only temporary mechanical support to the injury site, rather than a stable
platform

for

axonal

regeneration.

Recently,

poly(N-isopropylacrylamide)-co-

poly(ethylene glycol) (PNIPAAm-PEG) has been proposed as a thermoresponsive, nondegradable hydrogel scaffold for SCI repair (47). The scaffold exhibits a phase transition
between ambient and physiological temperature, enabling it to be injected at room
temperature and form a space filling hydrogel at the injury site. Comolli and colleagues
(2009) have demonstrated that PNIPAAm-PEG (i) can be tailored to obtain mechanical
properties analogous to spinal cord tissue, (ii) is biocompatible and supports the
attachment and survival of bone marrow stromal cells, (iii) displays excellent mass and
volume retention, and (iv) can be used as a delivery vehicle for controlled release of
neurotrophic factors. Based on these findings, PNIPAAm-PEG represents a promising
multifunctional scaffold for neural tissue engineering applications; however, survival and
differentiation of cells throughout the 3-dimensional network, as opposed to those only
on the hydrogel surface, needs to be confirmed.
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2.5.3

Design Criteria of an Ideal Conduit
An effective nerve conduit will exhibit good biocompatibility, meaning that the

selected material elicits an appropriate immune response and does not demonstrate
extreme toxicity to cells (2, 41). The conduit must also have sufficient mechanical
properties that enable it to maximally support axonal outgrowth, without collapsing under
applied physiological stresses.
In an effort to minimize and overcome the effects of secondary injury, cells
should be seeded within the conduit that can replace and repair damaged cells, as well as
provide trophic support and molecular cues that stimulate axon regeneration (41); the
conduit must allow incorporation of these cells and support cell survival and
differentiation, which is best achieved with a three-dimensional network that closely
mimics the native tissue (48). This internal network should physically guide regenerating
axons across the lesion to the target cells to form functional synapses. Moreover, the
conduit network should contain interconnected pores, or void space, to promote tissue
integration and growth, and have a large surface area for cell attachment (41). Porosity
also facilitates cell migration, flow of nutrients and other constituents, and enables the
conduit to be used for delivery of trophic factors (46). Delivery of trophic factors,
however, should be in a controlled fashion that provides the necessary quantities and
types at the rates most permissive to axon regeneration (41).
An ideal conduit would be easily transplanted into the injury site, conform to the
shape of the cavity and be space filling (1, 47), which can be achieved with an injectable
material. A conduit that does not completely fill the cavity would contribute to an
adverse inflammatory response and glial scar formation (46, 47). Injectable materials
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would not only take the shape of the cavity at the injury site, but also fill irregular defects
and do not require pre-fabrication. In addition, trophic factors and cells can be uniformly
seeded and mixed within the material prior to injection. However, the solidification
process of the injected material must occur under mild conditions that support cell
survival (1).
One design element of current debate in the construction of a nerve conduit is
degradability, which has inherent advantages and disadvantages that should be
considered. On one hand, degradable conduits can be used to control delivery of trophic
factors during regeneration, and avoid the need for a permanent implant that can
potentially result in an unresolved inflammatory response (39). The rate of degradation
can also be tailored to match the rate of new tissue formation by altering the material
building blocks used in formulation (39, 41). On the other hand, degradable conduits
provide only temporary mechanical support that may become unstable and inhibit
complete axon regeneration (43, 47). If the conduit destabilizes, the injury site will be
prone to unsupported compressive stresses that can result in cell death and inflammation
– characteristics of SCI already known to inhibit functional recovery.

Likewise,

degradable conduits also risk the release of unfavorable breakdown components (43),
creating a more hostile environment. On a final note, the purpose of the conduit is to
physically guide regenerating axons across the lesion to the innervation target, while
minimizing the effects of secondary injury via trophic and cellular components. As the
conduit degrades, the environment responsible for supporting axon innervation and
functional recovery may also diminish (47). With these considerations in mind, the
research presented in this work supports the development of a non-degradable conduit.
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2.6 Intervertebral Disc Degeneration
Intervertebral disc (IVD) degeneration is a major cause of back pain, which is the
most common medical problem in the world and affects nearly 80% of the population
(11, 16). Indeed, a recent autopsy study found that 97% of individuals aged 50 years or
older showed apparent IVD degeneration (11). Signs of disc degeneration are also
apparent in approximately 20% of the teenage population (13, 14). Due to its prevalence,
back pain not only accounts for individual suffering, but also accounts for billions of
dollars spent annually in societal costs of time lost from work, treatment, and
compensation of lost wages. As individuals continue to live longer, the associated health
costs will also increase, amplifying the need for alternative, early treatments to
degeneration.
Although not limited to, IVD degeneration is often the result of natural
physiological changes that occur within the disc as it ages, which subsequently
compromise the weight-bearing and mobility functions of the disc (14, 49, 50). The most
commonly affected discs are at the lumbar levels (51), which may carry loads up to 250%
of the total body weight (52). As mentioned earlier, the nucleus pulposus predominantly
consists of the proteoglycan aggrecan, which contains glycosaminoglycans that carry a
fixed negative charge and generate an osmotic swelling pressure within the disc (53).
However, the proteoglycan content in the nucleus decreases naturally over time, causing
decreased hydration and impaired function. During the first 10 years following birth, the
resident cells of the nucleus begin to change phenotype. Post-natal cells within the
nucleus are 30 – 40 µm in diameter, frequently appear in clusters, and have actin-
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filament-bounded intracellular vacuoles that contain glycosaminoglycans, enabling the
cell to generate an osmotic swelling pressure (53). In contrast, mature cells of the
nucleus are only 10 µm in diameter and lack these intracellular vacuoles. In addition,
mature cells have an increased expression of collagen I. As a result, type II collagen of
the nucleus is replaced by denser type I collagen that tends to crosslink and form an even
denser tissue, inhibiting metabolic exchange within the disc (14). Although the cause of
this cellular transition is unclear, mechanical and nutritional changes in the disc
microenvironment are thought to play a role in inducing cell apoptosis or differentiation.
As the disc ages, the vertebral endplates begin to thin with formation of clefts
and fissures.

The endplates plates are eventually replaced by fibrocartilage and

demonstrate reduced permeability, limiting metabolic exchange (14, 16). In turn, the
reduced nutrient supply diffusing through the endplates leads to altered functions and
increased death of the cells the comprise the IVD. Similarly, excessive mechanical
stresses applied to the disc may trigger deleterious biochemical events, such as
upregulation of cytokines and proteases, which weaken it and cause localized tissue
injury (51, 53). As early as the third and fourth decades of life, the annulus begins to
show fissures and an uneven balance of cell death and proliferation develops, which leads
to the invasion of vasculature and may play a role in spinal pain (14, 16).
These and other histological changes alter the biomechanical properties of the
disc (16). For instance, as the annulus or endplates begin to degenerate, a loss of restraint
and opposing force to the nucleus occurs.

Likewise, when the nucleus become

dehydrated, the annulus experiences abnormal loading forces. These changes can give
rise to bulging, herniation, and reduced disc height, as shown in Figure 2.5 (14, 16).
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Radial tears, cracks and fissures that occur within the annulus enable the nucleus to
migrate through the tear. In turn, this causes stretching and delamination of the annulus,
which often impinges on the surrounding nerves and causes back pain (49). Due to the
avascular structure of the IVD and the limited amount of viable cells present, it is often
difficult for the body to naturally repair the disc at the onset of degeneration (16); hence,
degeneration typically results in collapse of the intervertebral space (50) and is one of the
most common causes of morbidity (16, 54).

2.6.1

Treatment of Disc Degeneration
Degeneration of the IVD can be treated conservatively, with medication and

physical therapy, or surgically, which can involve spinal fusion, total disc replacement or
replacement of only the nucleus pulposus (55). The aim of these methods, however, is
symptomatic relief rather than repairing the degenerated tissue. Alternatively, tissue
engineering of the IVD provides an opportunity to not only restore the function of the
disc, but also regenerate the natural tissue in situ.

2.6.1.1 Conservative Treatments
Modalities for treating degeneration in a conservative manner include antiinflammatory pain medications, rehabilitation programs involving exercise therapies to
improve core stability and motion and strengthen muscles, massage therapy, acupuncture,
and other nonoperative techniques (56, 57). When these therapies fail to relieve the back
pain associated with disc degeneration, surgical intervention is used to remove the
damaged or altered, painful disc tissue.
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2.6.1.2 Surgical Interventions
The major surgical treatment for disc degeneration is currently spinal fusion (11,
56, 58), through which the degenerated disc is removed and the vertebral bodies above
and below the disc space are fused together with a bone graft (55). The spinal segment is
further stabilized with an interbody cage or spacer, typically manufactured from titanium
or carbon fiber composites (59, 60). Although this method is generally successful in
alleviating pain, fusion of the vertebrae limits flexibility and may induce degenerative
changes and alter biomechanics at adjacent spinal segments. Due to these limitations,
total disc replacement modalities are emerging that aim to preserve spinal motion by
replacing the damaged IVD with an intervertebral prosthesis (11, 55, 56, 58).
Currently, the CharitéTM Artificial Disc (Johnson & Johnson) and the ProDiscTML (Synthes Spine, Inc.) are approved by the Food and Drug Administration (FDA) to treat
pain associated with IVD degeneration. The CharitéTM Artificial Disc consists of a
sliding ultra-high molecular weight polyethylene core and two cobalt-chrome endplates,
which anchor the core to the upper and lower vertebral bodies. Together, the core and
endplates re-establish the natural disc height and provide movement at the corresponding
spinal segment. Similarly, the ProDiscTM-L consists of an ultra-high molecular weight
polyethylene convex inlay that fits between two cobalt-chrome endplates with a ball-andsocket design. In contrast to the CharitéTM Artificial Disc design, only the top endplate of
the ProDiscTM-L articulates with the plastic inlay to facilitate movement, while the
bottom endplate snap-locks with the inlay (59). Despite the advantages of total disc
replacement, these intervertebral prostheses are indicated for the treatment of only single
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level lumbar discs, after non-surgical treatment modalities have proven to be ineffective.
Total disc replacement devices also require invasive surgery to implant the artificial disc,
and can lead to complications involving migration, prolapse and failure of the prosthesis
as it wears with time (56, 59).
Overall, these surgical interventions serve as late-stage strategies for symptomatic
relief from IVD degeneration and do not aim to simultaneously repair the damaged tissue
to restore disc functionality.

2.6.1.3 Nucleus Pulposus Replacement
An emerging alternative to total disc replacement is replacement of the nucleus
pulposus alone, an earlier-stage intervention strategy that not only provides a lessinvasive surgical procedure, but also recreates the biomechanical function of the IVD
(58). Nucleus pulposus replacements redistribute loads to the natural annulus fibrosus,
while maintaining the disc height and preserving movement of the spinal segment.
Although the FDA has yet to approve a partial disc replacement device, several are under
investigation and a few devices, such as the HydraFlex Prosthetic Disc Nucleus
(Raymedica, Inc.), have received regulatory approval outside of the United States (61).
The HydraFlex consists of a preformed hydrogel core composed of polyacrylamide and
polyacrylonitrile encased in a polyethylene-woven jacket. Other potential preformed
devices being studied include the Aquarelle (Stryker Spine), a hydrogel fabricated from
poly(vinyl alcohol); NeuDisc (Replication Medical), a hydrogel composed of a modified
hydrolyzed polyacrylonitrile; NuBac (Pioneer Surgical Technology), a two-piece
mechanical device based on poly(etheretherketone); Newcleus (Zimmer, Inc.), a one-
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piece mechanical device fabricated from poly(carbonate urethane); and Regain (EBI
Medical Systems), a one-piece mechanical device containing pyrolytic carbon (58, 61,
62). Since these devices are preformed, surgical procedures are still necessary albeit less
invasive than traditional approaches.
With this in mind, an injectable nucleus pulposus replacement could have
important clinical consequences because it can be implanted using a non-invasive
procedure, minimizing tissue damage and subsequent implant migration (58). Based on
this precedence, several injectable devices are being explored for nucleus pulposus
replacement, such as the BioDisc (CryoLife), an albumin and glutaraldehyde hydrogel;
Dascor (Disc Dynamics), a polyurethane-based system; Hydrafil (Synthes Spine), a
hydrogel containing poly(vinyl alcohol) and poly(vinyl pyrrolidone); and NuCore (Spine
Wave), a silk and elastic copolymer (58, 61, 62). The major caveat to these devices is
that formation occurs post-injection via in situ polymerization, which can result in heat
generation at the injection site and leaching of potentially toxic unreacted monomer (58).
As a result, there remains an unmet need to develop safe and effective, minimally
invasive nucleus pulposus replacements that can reestablish healthy disc function at early
stages of degeneration.

In this regard, tissue engineering-based approaches appear

particularly promising.

2.6.2

Tissue Engineering of the Intervertebral Disc
Alternative treatments are needed that not only target pain relief, but also non-

invasively repair or regenerate the natural tissue and restore the functionality of the IVD.
Recently, the potential for tissue engineering approaches to meet these demands has been
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realized. Such modalities include cell-based therapies, gene therapy and scaffold-based
repair of the disc tissue. Cell proliferation and extracellular matrix production can be
stimulated by locally delivering, or injecting, growth factors such as bone morphogenetic
protein 7, transforming growth factor-β, and growth/differentiation factor 5 (13, 53, 59).
Similarly, cytokine inhibitors can be used to inhibit tissue breakdown caused by cytokine
stimulation. Practically, however, the success of directly delivering growth factors and
cytokine inhibitors is limited by the short biological half-lives of these agents, in addition
to rapid diffusion from the injection site (13, 53, 59). These limitations have led to the
investigation of gene therapy, a process by which the gene of interest, codes for either the
target growth factor or cytokine inhibitor, is transferred into target cells.

This enables

the cells to produce and maintain a high level of the relevant protein within the
degenerated disc tissue, and avoids the need for repeated injections. Nevertheless, gene
therapy is far from clinical use due to difficulties associated with gene insertion into disc
cells, proper selection of therapeutic genes, and low density of viable cells in degenerated
discs (13).
In cell-based tissue engineering approaches, cells are delivered locally to the
degenerated disc to replenish the cell density, and ultimately provide signaling cues or
produce extracellular matrix to revive the tissue (53). Cell therapy can be used in
conjunction with gene therapy, independently, or in combination with scaffolds. Indeed,
both mesenchymal stem cells and autologous nucleus pulposus cells, those derived from
a healthy disc and delivered to the degenerated disc of the same individual, have been
shown to delay degeneration in experimental models when administered via injection (11,
59). It is important to note here that the use of autologous cells is limited in clinical
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application; the surgical procedures necessary to harvest such cells from healthy discs can
induce degeneration, while cells harvested from degenerated discs typically possess an
altered phenotype as a result of biochemical changes that occur during the degenerative
cascade. In contrast to other cells, stem cells are unspecialized cells that can proliferate
and differentiate to yield specialized cell types when triggered by internal and external
signals (2). Although promising, stem cells lack the cell specific markers that delineate
disc cell phenotypes, which can hinder the ability to quantify stem cell differentiation
(63).
Aside from complications associated with cell selection, cell therapies will only
be effective if the disc environment is conducive to maintaining cell activity. In this
regard, nutrient supply and mechanical load are two critical factors of major concern. As
disc degeneration progresses, the vertebral endplates can become calcified, inhibiting
nutrient supply to the cells and ultimately leading to cell death within the disc. Despite
the introduction of healthy cells into the degenerated environment, an adequate nutrient
supply is necessary to support the implanted cells. Hence, cell therapy may be effective
only when a nutritional microenvironment exists.

By the same token, if cells are

implanted into the degenerated disc without additional support, abnormal forces exerted
on the cells may result in abnormal matrix production and consequently lead to
degeneration of other spinal structures (11).
To this end, cell therapy can be implicated with the aid of scaffolds, in which cells
are seeded onto a biomaterial substrate that restores disc height and provides both
mechanical support and biochemical cues to the tissue. On the cellular level, scaffolds
serve as a synthetic extracellular matrix that (i) organizes cells into a three-dimensional
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architecture; (ii) presents stimuli; and (iii) guides the cellular remodeling process (55,
64). Scaffolds can also be used as delivery vehicles for local retention of not only cells,
but also bioactive molecules such as growth factors. To date, a host of cell-seeded
scaffolds have been studied for tissue engineering of the IVD (55, 65). Techniques
include engineering scaffolds for replacement of only the nucleus pulposus or annulus
fibrosus, as well as biphasic scaffolds (66, 67) intended to replace both elements of the
IVD, depending on the target stage of degeneration.

Replacement of the nucleus

pulposus is an attractive approach to treating early-stage degeneration; however, such an
approach can be considered only in cases involving a healthy, intact annulus fibrosus.
Advanced disc degeneration will likely require strategies that address multiple
components of the IVD.
In a study by Bron and colleagues (2012), IVD cells were seeded onto scaffolds
composed of type I collagen, which were subsequently implanted as a nucleus pulposus
replacement following discectomy. Although this study revealed migration of seeded
nucleus pulposus and annulus fibrosus cells into the dense collagen network, the stiffness
of the scaffold did not mimic that of native nucleus pulposus tissue, which may be
attributed to the lack of type I collagen in native IVD tissue (68). Moreover, migration
distances of nucleus pulposus cells were significantly higher than for annulus fibrosus
cells, which are more likely to be present in surrounding tissue following discectomy of
the nucleus. In another study, collagen-based scaffolds were used to demonstrate the
ability of growth factors to stimulate ECM proliferation in vitro by rabbit nucleus
pulposus cells (69). Collagen scaffolds have also been shown to support the viability and
differentiation of bone marrow-derived mesenchymal stem cells (MSCs) into
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chondrocytes (70), which resemble the cells of the nucleus pulposus. Indeed, Bertolo and
colleagues (2012) observed that both collagen and gelatin scaffolds were more effective
than alginate and chitosan in enhancing gene expression of aggrecan and collagen types I
and II, as well as proteoglycan accumulation. However, the expression of chondrogenic
markers by MSCs was significantly lower than that by native nucleus pulposus cells.
Collagen scaffolds are also characterized as having weak mechanical and degradative
resistance properties (71), which can be detrimental to new tissue formation.
In order to more accurately emulate the biological environment of nucleus
pulposus, Huang and colleagues (2010) constructed a sponge-like scaffold from collagen
type II, hyaluronan and chondroitin 6-sulfate, the principal components of nucleus
pulposus ECM. Rabbit-derived nucleus pulposus cells were seeded on top of the scaffold
and in vitro cell proliferation and gene expression were monitored over 28 days. Cell
count, measured by optical density, was significantly higher after 28 days relative to day
1, although no significant difference was report between days 14 and 28. The scaffolds
also exhibited an increase in sGAG content, as well as collagen type II and aggrecan gene
expression in comparison to a control cell monolayer (72). Despite these promising
findings, clinical use of this tri-copolymer scaffold would require invasive procedures to
implant the nucleus pulposus replacement following discectomy. Moreover, the scaffold
requires further characterization to ensure that the required mechanical criteria are met.
In addition to these scaffold materials, researchers have investigated the use of
demineralized bone particle and poly(lactic-co-glycolic acid) composites seeded with
nucleus pulposus cells (73), which resulted in tissue formation and proteoglycan secretion
but also caused secretion of inflammatory agents due to the acidic breakdown
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components of the polymer.

In other work, decellularized porcine-derived nucleus

pulposus scaffolds have been shown to support the survival of human adipose derived
stem cells over 7 days, and exhibit comparable swelling characteristics, water content,
and mechanical properties to those of human nucleus pulposus tissue (74). However,
characterization of human stem cell differentiation and in vivo biocompatibility is
ongoing.
In an effort to develop less invasive, early stage nucleus pulposus replacement
devices, Halloran and colleagues (2008) investigated injectable, enzymatically
crosslinked scaffolds comprised of atelocollagen type II and varying concentrations of
aggrecan and hyaluronan, seeded with nucleus pulposus cells. Incorporation of aggrecan
into the cell-seeded composite caused a significant reduction of not only scaffold volume,
but also sulfated glycosaminoglycan (sGAG) retention after 7 days (71). In contrast,
crosslinked atelocollagen type II-based composite scaffolds without aggrecan resisted
scaffold volume reduction, and displayed improved retention of sGAG content and
mechanical integrity. In addition to these findings, the scaffolds were reported to support
cell viability and proliferation over 7 days in vitro; however, differentiation of
mesenchymal stem cells into nucleus pulposus-phenotypic cells was not investigated, and
the ability of the scaffolds to support new tissue formation has yet to be determined (71).
More recently, Reza and colleagues (2010) investigated carboxymethylcellulose
(CMC)-based hydrogels, seeded with nucleus pulposus cells, as potential scaffolds to
replace the nucleus pulposus. More specifically, the effects of molecular weight and
macromer concentration on cell viability and elastic modulus were characterized.
Although the scaffolds demonstrated a decrease in cell viability in vitro over 7 days,
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these changes were reported as insignificant and attributed to potential exogenous factors
(75). Based on the observed interplay between hydrogel degradation and new tissue
formation, a CMC-based hydrogel was established that experienced a temporal decrease
in mechanical properties. This reduction was counteracted by cell matrix production and
enabled the mechanical integrity of the hydrogel environment to be maintained (75). The
major caveat to this approach is the need for in situ photopolymerization, which can lead
to incomplete polymerization, heat generation and other undesirable and potentially toxic
effects.
Alternatively, functionalized peptides have been explored recently that
spontaneously self-assemble into nanofiber hydrogels upon exposure to physiological
environments (76). For example, Wang and colleagues (2011) designed a functionalized
nanofiber peptide scaffold by mixing solutions of commercially available self-assembling
peptide PuraMatrix and functionalized peptide RLN. The scaffold elicited suitable in
vitro cytocompatibility with nucleus pulposus cells, in addition to significant surface cell
adhesion and spontaneous migration into the hydrogel. Proteoglycan and collagen type II
gene expression was also supported and significantly enhanced relative to a nonfunctionalized PuraMatrix control (76). Despite these promising findings, the mechanical
properties of the scaffold were not reported and in vivo characterization is ongoing.
Of particular interest is the in situ forming scaffold comprised of the branched
copolymer poly(N-isopropylacrylamide)-co-poly(ethylene glycol) (PNIPAAm-PEG).
Vernengo and colleagues (2007) characterized the swelling, dissolution and compressive
mechanical properties of the scaffold over 90 days and further assessed the stress
relaxation behavior of the hydrogel following a 30 day in vitro immersion period.
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Incorporation of PEG into the hydrophobic PNIPAAm network imparted the hydrogel
with tunable mechanical properties that can be tailored to the load-bearing requirements
of the nucleus pulposus, and a high equilibrium water content desirable for nutrient
diffusion within the largely avascular IVD (58). In a follow up study (77), incorporation
of PEG was also shown to significantly enhance the dimensional recovery of the
hydrogel.

Moreover, PNIPAAm-PEG scaffolds display excellent mass and volume

retention in vitro (47), as well as in vitro cytocompatibility and in vivo biocompatibility
(78). In addition to these findings, PNIPAAm-PEG scaffolds have been characterized as
suitable carriers for local delivery of growth factors. In short, such a scaffold can be used
for nucleus pulposus replacement as a minimally invasive, injectable, multifunctional
scaffold to locally delivery growth factors and cells and support new tissue formation.
The major limitation to this approach is the non-biodegradability of the scaffold; although
the scaffold is porous in structure allowing for tissue ingrowth, an ideal nucleus pulposus
replacement would serve as a temporary dynamic, structural support until natural tissue is
formed.
Presently, there is no general consensus regarding which tissue engineering
approach to IVD repair will be optimal. Given the complex disc degeneration process
and variability among individuals, it is conceivable that treatment will reflect the extent
of degeneration on a case-by-case basis.

2.6.3

Design Criteria of Scaffolds for Nucleus Pulposus Replacement
An ideal nucleus pulposus replacement should mimic the architectural, biological

and mechanical features of native ECM found within a healthy nucleus pulposus;
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however, the complexity of ECM limits the ability of an engineered scaffold to exactly
mimic it. Despite this, several analogous functions of the scaffold have been identified
(79).
The ECM not only provides a physical environment for cells within the tissue to
proliferate, migrate and respond to signals, but also offers structural and mechanical
stability to the tissue. As a result, the scaffold should be biocompatible, and support cell
viability, proliferation, migration and differentiation into cells resembling the phenotype
of nucleus pulposus cells. Architecturally, the structure must contain interconnected
pores to allow proper nutrient and metabolite transport to and from the tissue given the
inherently avascular nature of the IVD. This void space also enables new tissue to form
and integrate throughout the scaffold. Mechanically, the scaffold must completely fill the
defect or void space of the tissue being replaced to provide stability to the surrounding
tissue. It is critical that the mechanical properties of the scaffold mimic those of the
native nucleus pulposus to restore normal kinematic function to the degenerated motion
segment and to eliminate adjacent level effects (59). Moreover, the nucleus pulposus
replacement should require minimally invasive procedures for implantation to minimize
damage to the surrounding, healthy tissue.
In addition to providing structural support for cells, the ECM actively provides
cues to regulate the activity of nearby cells, and may also store and potentiate the actions
of growth factors. An ideal scaffold would be bioactive to recapitulate these functions;
for instance, the scaffold should interact with cells and other components to facilitate and
regulate activities such as proliferation and differentiation. In this regard, the surface
topography and 3-dimensional structure of the scaffold can have important consequences
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on cell morphology and alignment. However, cellular interaction can also be achieved by
using the scaffold as a delivery vehicle for growth factors that can provide the necessary
biological cues to stimulate regeneration. Therefore, the scaffold should support the
retention of exogenous growth factors and exhibit controlled release upon implantation
(79).
Unlike current treatment modalities for IVD repair, nucleus pulposus ECM is
dynamic in nature to allow remodeling in response to tissue processes. As a result, the
scaffold should be biodegradable and degrade at a controllable rate, equal to the rate of
new matrix production, without compromising the mechanical stability of the
environment (79). The breakdown components of the scaffold must also have acceptable
biocompatibility to avoid an inflammatory response or immune reaction, which can have
a detrimental impact on the function of the scaffold.
Considering these criteria, an injectable, biodegradable hydrogel that can solidify
under mild conditions following injection would be appropriate. By this approach, cells
and growth factors can be suspended within the hydrogel solution, delivered to the
degenerated site in a minimally invasive manner, and become encapsulated within the
scaffold upon solidification.

2.7 Hydrogels
One of the major challenges in tissue engineering is constructing an environment
that mimics the complex extracellular matrix of native tissue and supports cell
proliferation and new tissue formation (48). Extracellular matrix (ECM) is a dynamic
network that provides both structural and anchoring support to its surrounding cells and
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influences the fate and function of these cells via cell-matrix interactions. As a result,
artificial matrices or scaffolds used in tissue engineering applications should not only
support the growth and maintenance of cells, but also mimic the mechanical, chemical
and biological characteristics of the native ECM, including nutrient transfer, waste
removal, gas exchange and signal transduction (48). Suitable scaffolds can be engineered
from hydrogels, which possess structural similarities of native ECM. Hydrogels are
insoluble, three-dimensional networks composed of hydrophilic polymeric chains that are
chemically or physically crosslinked together. Characteristically, hydrogels are soft and
elastic materials with high water content that swell, but do not dissolve, in the presence of
water or physiological fluids (48, 80). As scaffolds, hydrogels can have porous structures
that provide the framework necessary to support tissue ingrowth and regeneration (40).
The mechanical properties of hydrogels can also be easily modified to mimic those of the
native tissue by adjusting the composition of polymers and the crosslinking density (48).
Particularly attractive hydrogels for tissue engineering applications are those that
respond to environmental stimuli, such as changes in temperature. In addition to the
aforementioned properties, thermoresponsive hydrogels undergo a phase transition that
can enable these materials to be used as injectable scaffolds that form in situ. Such
scaffolds could be delivered in a minimally invasive manner, completely fill a cavity or
defect,

and

circumvent

the

need

for

patient-specific

prefabrication

(1).

Thermoresponsive hydrogels could also be used to uniformly seed cells, drugs and
growth factors within the scaffold prior to injection.
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2.8 Poly(N-isopropylacrylamide)
Poly(N-isopropylacrylamide),

denoted

PNIPAAm,

is

a

synthetic,

non-

biodegradable, thermoresponsive polymer. Its chemical structure is provided in Figure
2.6. Aqueous solutions of PNIPAAm exhibit a sharp phase transition at or near 32°C,
referred to as the lower critical solution temperature (LCST) (58, 80, 81).

At

temperatures below the LCST, water hydrogen bonds with the polar amide groups of
PNIPAAm, forming a miscible, free-flowing solution. However, above the LCST, the
hydrophobic isopropyl group and backbone of PNIPAAm destabilize the water-amide
interactions (82). This reduces the solubility of PNIPAAm, causing collapse of the
network and dramatic phase separation.
The solution to gel transition of PNIPAAm hydrogels can be explained by
thermodynamics, based on the principle that the system will seek the lowest possible free
energy. The expression for free energy is provided in Equation 2.1.

Equation 2.1

∆𝐺 = ∆𝐻 − 𝑇∆𝑆

Binary aqueous solutions of PNIPAAm exhibit three types of interactions: (i) between
polymer molecules; (ii) between polymer and water molecules; and (iii) between water
molecules (81). Below the LCST, the formation of hydrogen bond interactions between
the water molecules and the polymer chain results in a favorable enthalpic gain (-ΔH) that
lowers the free energy of dissolution (83, 84). This energy gain compensates for the
energy required from the system to create a more ordered cluster, described as an
entropic loss (-ΔS), and allows the hydrated polymer to exist in a thermodynamically
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stable state. However, the water-PNIPAAm hydrogen bonds restrict the motion of the
water molecules, causing a reduction in orientational entropy (82). As the temperature
increases above the LCST threshold, the enthalpic gain of the water-polymer hydrogen
bonds is weakened (83) and the entropic losses associated with the water-polymer
interactions become more unfavorable. To decrease the free energy of the system, the
hydrogen bonds are broken, which increases both the orientational and positional
freedom of the water molecules, and the water-water interactions and polymer-polymer
interactions result in phase separation. In hydrated systems of crosslinked PNIPAAm,
the polymer exhibits a reversible volume phase transition from a swollen, hydrophilic
state to a shrunken, hydrophobic state at the LCST (80).
Since the phase transition of PNIPAAm conveniently occurs between ambient and
body temperature, it is one of the most widely explored thermoresponsive polymers (1,
47, 80, 83). PNIPAAm can be injected at room temperature and forms a thermally
induced space-filling gel at physiological temperature. Due to the fact that PNIPAAm
hydrogels do not require in situ polymerization, there is no risk of leaching potentially
toxic unreacted monomer or generating excess heat at the injection site (58). However,
PNIPAAm hydrogels are typically a mechanical mismatch with the native tissue when
polymerized as a homopolymer (77). At physiological temperatures, water molecules
associated with the isopropyl groups of PNIPAAm are released into the bulk aqueous
phase. This expulsion of water causes the homopolymer to become stiff and exhibit poor
elastic recovery, which can be detrimental in load-bearing tissue applications. In order to
improve the mechanical properties of PNIPAAm, NIPAAm can be polymerized in the
presence of hydrophilic macromers, such as poly(ethylene glycol) dimethacrylate
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(PEGDM) or chondroitin sulfate, to yield PNIPAAm-PEG and PNIPAAm-CS branched
copolymers, respectively.

2.9 Poly(ethylene glycol)
Poly(ethylene glycol) (PEG) is a synthetic, non-biodegradable, hydrophilic
polymer (85) that is currently FDA-approved for use in several biomedical applications
(86, 87). As shown in Figure 2.7, PEG is linear in structure and contains terminal
hydroxyl groups, which can be functionalized for hydrogel formation (85).

PEG

hydrogels are excellent candidates as biomaterials in tissue engineering applications
because these systems exhibit biocompatibility, non-immunogenicity, high permeability
and tunable properties (85, 88, 89). As a result, PEG hydrogels have been implicated for
use in cartilage repair (90, 91), as drug delivery vehicles (86) and cell-based scaffolds
(92), and in adhesive medical applications (87).
Recently, PEG has been incorporated into PNIPAAm-based hydrogels to improve
the swelling and elasticity of the injectable scaffold for both spinal cord injury repair (47)
and nucleus pulposus replacement (58). Prior work has demonstrated that hydrogels
composed of PNIPAAm lightly crosslinked with PEGDM exhibit an increased water
content and a reduced compressive modulus relative to PNIPAAm homopolymers,
without compromising the LCST (58, 77).

Indeed, PNIPAAm-PEG branched

copolymers can be tailored to exhibit compressive mechanical properties similar to that
of the native tissue (47, 58), and display excellent mass and volume retention in vitro
(47). Moreover, PNIPAAm-PEG scaffolds have been investigated in vitro for delivery of
neurotrophic factors, including BDNF and neurotrophin-3 (47). The scaffold exhibited a
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minimal burst release, followed by a linear release for 4 weeks, at which point
approximately 80% of the loaded neurotrophic factors was released and biologically
active. Additionally, PNIPAAm-PEG has been shown to support proliferation of human
bone marrow stromal cells for at least 30 days in vitro (47). However, analysis was
limited to examining the cells only on the surface of the polymer, rather than within the
3-dimensional network.

Nevertheless, these results suggest that PNIPAAm-PEG

hydrogels can be used as multifunctional injectable scaffolds in spinal cord injury to: (i)
fill a defect or cavity; (ii) provide mechanical support at the injury site; (iii) support cell
survival and attachment; and (iv) enable controlled delivery of neurotrophic factors. A
goal of this work is to demonstrate that PNIPAAm-PEG hydrogels in fact support cell
survival and differentiation throughout the 3-dimensional network.

2.10

Chondroitin Sulfate
Chondroitin sulfate (CS) is a glycosaminoglycan (GAG) that consists of repeating

disaccharide units of D-glucuronic acid and N-acetyl-D-galatosamine, sulfated at the C4 or
C6 positions (93, 94), as shown in Figure 2.8.

CS is a predominant GAG in the

intervertebral discs and a component of aggrecan, the cardinal proteoglycan of the
intervertebral discs (10). In general, GAGs interact with growth factors and cytokines,
inhibit proteases, and are involved in cell adhesion, migration, proliferation and
differentiation (95). As a result, GAGs such as CS have been proposed in cartilage and
other tissue engineering applications (93, 96, 97).

CS, in particular, exhibits anti-

inflammatory activity (93, 97, 98) and its biological activity has been shown to enhance
cartilage tissue regeneration from mesenchymal stem cells (98). CS also attracts and
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retains water due to the ionic, carboxyl and sulfate radicals within its structure (10).
Since CS is a natural material, it can be incorporated into scaffolds based on synthetic
polymers to enable degradation of an otherwise permanent structure, and provide space
for matrix production and tissue regeneration. In this work, CS is incorporated into
PNIPAAm networks to improve the swelling and mechanical properties of the hydrogel
for nucleus pulposus replacement.
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Figure 2.1 Neuron anatomy.
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Figure 2.2 Organization of the spinal cord. Left: Levels of the spinal cord. Modified
from (9). Right: A cross-section of the spinal cord, revealing the butterfly-shaped gray
matter at the core and a surrounding ring of white matter. Image from (6).
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Figure 2.3 Organization of intervertebral discs. Left: A schematic of a spinal segment,
depicting an intervertebral disc separating two vertebral bodies. Right: Anatomy of an
intervertebral disc. The disc contains a central gel-like nucleus pulposus, surrounded by
an outer annulus fibrosus and an upper and lower vertebral endplate. Images from (13).
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Figure 2.4 Lesion cavity resulting from injury to the central nervous system.
Modified from (7).
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Figure 2.5 Outcomes of disc degeneration.
(Image from: http://boneandjointsclinic.com/Disc_Replacement.htm
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Figure 2.6 Chemical formula of poly(N-isopropylacrylamide) (PNIPAAm).
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Figure 2.7 Chemical formula of linear poly(ethylene glycol) (PEG).

58

Figure 2.8 Chemical structure of chondroitin sulfate A (CS) disaccharide unit.
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Chapter 3
Research Goals
Specific Aim 1: Synthesize and characterize a class of thermoresponsive hydrogels
composed of poly(N-isopropylacrylamide) and poly(ethylene glycol) for repair of the
injured spinal cord. Demonstrate ability of an injectable PNIPAAm-PEG scaffold to
support survival and proliferation of cells seeded within the matrix.

Specific Aim 2: Synthesize a class of degradable thermoresponsive hydrogels composed
of poly(N-isopropylacrylamide) and chondroitin sulfate-A (PNIPAAm-CS) for repair of
the degenerated intervertebral disc, and characterize the chemical structure by Nuclear
Magnetic Resonance (NMR) Spectroscopy.

Specific Aim 3: Characterize and examine the effects of composition on the swelling and
mechanical properties of injectable PNIPAAm-CS hydrogels.

Specific Aim 4: Investigate the degradation behavior and cytocompatibility of
PNIPAAm-CS hydrogels to evaluate the potential of these scaffolds to serve as threedimensional tissue engineering constructs for the intervertebral disc in vitro.
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Chapter 4
Synthesis and Evaluation of PNIPAAm-PEG Scaffolds for Spinal Cord Repair
4.1 Introduction
Trauma to the spinal cord has debilitating and irreversible consequences as a
result of neural tissue damage at the injury site. Due to the inability of the CNS to
regenerate damaged axons, an unfavorable physical gap is formed at the injury site that
results in permanent functional loss, creating a communication barrier between the brain
and body (6). As a result, spinal cord injury (SCI) generally results in a reduced quality
of life.

The difficulty in repairing the spinal cord is primarily due to the hostile

environment created at the injury site following the initial impact. Therefore, current
efforts to SCI have been driven towards creating a favorable and stable
microenvironment supportive of axon regeneration (39). In one approach, an injectable
hydrogel is proposed as an injectable scaffold that can bridge the spinal cord lesion and
provide permanent support for regenerating axons. The hydrogel is composed of a
poly(N-isopropylacrylamide) backbone with polyethylene glycol graft chains, denoted
PNIPAAm-PEG, and exhibits a lower critical solution temperature (LCST) near 32°C
(47). This property allows the gel to form in situ, eliminating the risk of excess reactants.
Prior work by Comolli and colleagues (2009) demonstrated that PNIPAAm-PEG
copolymers could be easily tailored to match the mechanical properties of native neural
tissue, and displayed excellent mass and volume retention in vitro. In a rodent model of
SCI, PNIPAAm-PEG completely filled an irregularly shaped defect via minimally
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invasive administration, and did not elicit greater host inflammatory responses or scar
formation than commercially available matrices (78). As scaffolds, PNIPAAm-PEG can
be used to locally deliver neurotrophic factors (47, 78), which have been shown to
promote neuronal survival and axon regeneration, and have been shown to support cell
attachment and proliferation in vitro (47).

Specifically, the viability of human

mesenchymal stem cells seeded within thin PNIPAAm-PEG discs was investigated over
31 days using a dual fluorescent stain; however, analysis was limited to examining the
cells only on the surface of the scaffold. In this aim, immortalized human embryonic
kidney cells (HEK) and primary rat fibroblasts are cultured within 3-dimensional
PNIPAAm-PEG copolymers and cell viability throughout the hydrogel network is
investigated. These cells lines were chosen based on ease of culture and relevancy to
spinal cord injury models. Immortalized HEK can be passaged indefinitely without
compromising the morphology and phenotype of the cells, and may have properties of
immature neurons (99), while fibroblasts are one of the most common cell types found in
connective tissue and play a key role in wound healing.

4.2 Experimental Section

4.2.1

Materials
N-isopropylacrylamide monomer was purchased from Sigma-Aldrich (St. Louis,

MO) and recrystallized in n-hexane before use. Polyethylene glycol (PEG) diol (Mn =
8000 g/mol) and 2,2’-azobisisobutyronitrile (AIBN) were purchased from Sigma-Aldrich
(St. Louis, MO) and used as received. Triethylamine (Sigma-Aldrich, St. Louis, MO)
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and methacryloyl chloride (97%, Alfa Aesar, Ward Hill, MA) were stored with molecular
sieves overnight before use. All other chemicals were commercially available and used
as received.

4.2.2

PEG Methacrylation
PEG dimethacrylate (PEGDM) was synthesized from PEG 8000 and

methacryloyl chloride using previously reported methods (100). Briefly, PEG 8000 was
dissolved in anhydrous dichloromethane (DCM) and reacted with an excess of
methacryloyl chloride and triethylamine, under nitrogen, at 4°C for 24 h and at room
temperature for an additional 24 h. The reaction mixture was precipitated in chilled
diethyl ether, vacuum filtered, and subsequently dried under vacuum overnight. PEGDM
was stored at 4°C in an amber vial until use. The average methacrylation efficiency of
PEG was verified by comparing the area under the integral for the vinyl protons (δ = 5.7
ppm, 6.1 ppm) to that of the PEG backbone (δ = 3.5 ppm), using Proton Nuclear
Magnetic Resonance (1H-NMR) Spectroscopy (400 MHz Varian Oxford AS400), in
deuterium oxide at 25°C.

4.2.3

PNIPAAm-PEG Synthesis
PNIPAAm-PEG branched copolymer scaffolds were prepared by free radical

polymerization, as described previously (58). Briefly, N-isopropylacrylamide (NIPAAm)
was dissolved in methanol and reacted with PEGDM in a 600:1 molar ratio of NIPAAm
monomer units to PEG branches, in the presence of the thermal initiator AIBN (200:1
molar ratio NIPAAm to AIBN). The reaction mixture was purged with nitrogen to
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remove free radical scavengers, sealed, and reacted at 65°C for 48 h.

Following

polymerization, the methanol was evaporated from the reaction mixture, and the resulting
copolymer was dried under vacuum, ground into a powder and purified in n-hexane at
50°C to remove excess reactants. Purified PNIPAAm-PEG was isolated by vacuum
filtration, dried under vacuum overnight, and lyophilized.

For further purification,

solutions containing 15 wt% PNIPAAm-PEG in deionized (DI) water were prepared.
The copolymer solutions were vortexed, stored at 4°C overnight for complete dissolution,
and heated to 37°C for gel formation over 48 h, replacing the DI water daily. Following
complete purification, excess water was removed from the PNIPAAm-PEG hydrogels,
and the copolymers were frozen, lyophilized and ground into a powder for use. The
hydrogel was analyzed by 1H-NMR to confirm both the incorporation of PEG along the
PNIPAAm backbone and the absence of the vinyl protons on the double bond of the
NIPAAm monomer or unreacted PEGDM.
Solutions containing concentrated (12.6 wt%) PNIPAAm-PEG were prepared
from the ground copolymer and Dulbecco’s Modified Eagle Medium (DMEM) (Gibco,
Invitrogen, Frederick, MD) containing 10% Fetal Bovine Serum (FBS) (HyClone
Laboratories, Inc., Logan, UT). The viscous copolymer solution was vortexed, stored at
4°C overnight for complete dissolution, and steam-sterilized prior to use.
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4.2.4

In Vitro Cell Viability within PNIPAAm-PEG Scaffolds

4.2.4.1 Human Embryonic Kidney Cell Culture
Immortalized human embryonic kidney (HEK) cells were purchased from
Invitrogen (293FT Cell Line, Frederick, MD) and cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Gibco, Invitrogen, Federick, MD) supplemented with 10% Fetal
Bovine Serum (FBS) (HyClone Laboratories, Inc., Logan, UT), 0.1 mM non-essential
amino acids, 6 mM L-glutamine, 1 mM sodium pyruvate, 1% Penicillin-Streptomycin
and 50,000 µg/mL Geneticin® Selective Antibiotic. Briefly, 5x106 cryopreserved HEK
cells were thawed quickly at 37°C, diluted in Phosphate Buffered Saline (PBS), and
pelleted at 1000 rpm for 5 min. The supernatant, containing dimethyl sulfoxide, was
aspirated and the HEK cells were resuspended in complete culture media without
Geneticin®. The cell suspension was plated on sterile petri dishes and incubated in a
water-jacketed CO2 incubator at 37°C and 5% CO2 overnight, allowing for cell
attachment. The next day, the culture medium was replaced with fresh, complete media
containing Geneticin®, and the cells were grown until >80% confluent. The cells were
then washed with PBS, detached with 0.1% trypsin Ethylenediaminetetraacetic Acid
(EDTA) solution, and centrifuged at 1000 rpm for 5 min. Detached HEK cells were
stained using trypan blue, which selectively colors non-viable cells, and counted on a
hemacytometer. HEK cells were routinely subcultured at a split ratio of 1:5 in complete
culture media, with viability >90%.
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4.2.4.2 Scaffold Preparation
A suspension containing approximately 3.9x105 HEK cells (P.7) per milliliter
DMEM complete culture media was prepared and added to PNIPAAm-PEG, yielding a
10 wt% copolymer solution seeded with 1.1x106 cells (7.9x104 cells/mL). HEK-seeded
scaffolds were prepared in sterile 60-mm petri dishes, at a volume of 300 µL copolymercell suspension per sample (2.4x104 cells/sample), and incubated at 37°C and 5% CO2 for
30 min. Following complete solidification, the samples were immersed in excess DMEM
culture media and incubated until analysis, refreshing the media regularly. Cell viability
over 25 days was assessed qualitatively and quantitatively using LIVE/DEAD and
Vybrant MTT assays (Molecular Probes, Invitrogen, Eugene, OR), respectively.
PNIPAAm-PEG scaffolds prepared without HEK cells were used as a control. A sample
size of n = 3 was used for quantitative analysis.

4.2.4.3 LIVE/DEAD Viability/Cytotoxicity Assay
HEK-seeded PNIPAAm-PEG scaffolds were qualitatively analyzed on days 0, 6,
13, 18 and 25 using a LIVE/DEAD stain (Molecular Probes, Invitrogen, Eugene, OR), as
per the manufacturer’s protocol. Briefly, 16 µL SYTO 10 green fluorescent nucleic acid
stain in dimethyl sulfoxide (Component A) and 16 µL DEAD Red nucleic acid stain in
20% dimethyl sulfoxide (Component B) were mixed into a common volume of 8 mL
PBS and the mixed dye solution was heated to 37°C. At each interval, excess culture
media was aspirated from the cell-seeded scaffold and the sample was washed with prewarmed PBS. LIVE/DEAD stain was applied over the scaffold and the sample was
incubated for an additional 30 min. Post-incubation, the stained sample was transferred
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onto a microscope slide using aseptic technique, covered by a coverslip and imaged using
an upright fluorescence microscope (Leica DM 5500B, Leica Microsystems,
Bannockburn, IL) with Slidebook software (Intelligent Imaging Innovations, Denver,
CO).

4.2.4.4 Vybrant MTT Cell Proliferation Assay
In parallel to the LIVE/DEAD assay, cell viability within PNIPAAm-PEG
scaffolds was quantified indirectly at days 0, 6, 13, 18 and 25 using an MTT assay
(Molecular Probes, Invitrogen, Eugene, OR), as per the manufacturer’s instructions. A
12 mM MTT stock solution was prepared by dissolving 5 mg 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) in 1 mL sterile PBS, and 1 g sodium dodecyl
sulfate (SDS) was dissolved in 10 mL 0.01 M HCl. The PNIPAAm-PEG scaffolds were
removed from the incubator and excess media was aspirated. Fresh, cool media was then
applied over the samples, allowing the hydrogels to re-dissolve. Following dissolution,
the samples were centrifuged at 1500 rpm for 5 min and excess media and polymer were
aspirated from the cell pellet. The cells were resuspended in 200 µL culture media and
20 µL MTT solution, and incubated at 37°C for 4 h. After 4 h, 200 µL SDS-HCl solution
was added to each sample and the solutions were incubated for an additional 18 h. Postincubation, 100 µL of the supernatant from each sample was transferred to a 96-well
plate and the optical density at 562 nm was read using an ELx800 Absorbance Microplate
Reader (BioTek Instruments, Inc.). Selected results were compared statistically using a
two-tailed t-test with a 95% confidence level.
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4.2.4.5 RF-GFP
Primary skin fibroblasts were isolated from female Sprague Dawley rats, as
previously described, (101) and infected in vitro with lentiviral constructs encoding the
green fluorescent protein (GFP) and brain-derived neurotrophic factor (BDNF). Postinfection, approximately 50% of the rat fibroblasts expressed GFP. The RF-GFP BDNFexpressing fibroblasts were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(Gibco, Invitrogen, Federick, MD) supplemented with 10% Fetal Bovine Serum (FBS)
(HyClone Laboratories, Inc., Logan, UT) and 1% Antibiotic-Antimycotic (Anti-Anti)
Solution (Cellgro, Mediatech, Inc., Manassas VA) containing 10,000 IU/mL penicillin
and 10,000 µg/mL streptomycin. The fibroblasts were grown to 70-80% confluency,
detached using 1% trypsin/EDTA and cell viability was determined using trypan blue
exclusion.
Approximately 6x105 viable fibroblasts (P.7) were suspended in 15 mL DMEM
culture media, and 2.5 mL of the cell suspension was mixed with PNIPAAm-PEG,
resulting in a 10 wt% copolymer solution seeded with roughly 1x105 RF expressing GFP
and BDNF.

Fibroblast-seeded scaffolds were prepared from the copolymer-cell

suspension at a volume of 200 µL/sample and incubated at 37°C and 5% CO2. Following
complete solidification, the scaffolds were immersed in excess DMEM culture media and
incubated until analysis, refreshing the media regularly. At days 1, 5 and 15, the samples
were washed in PBS and fixed in 4% PFA at 37°C for 15 min. The scaffolds were then
transferred to microscope slides and GFP expressing fibroblasts within PNIPAAm-PEG
were imaged using fluorescence microscopy (Leica DM 5500B, Leica Microsystems,
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Bannockburn, IL) with Slidebook software (Intelligent Imaging Innovations, Denver,
CO).

4.3 Results

4.3.1

PEG Methacrylation and Synthesis of PNIPAAm-PEG
The 1H-NMR spectrum for PEG dimethacrylate is shown in Figure 4.1. The

signals at δ = 5.7 ppm and δ = 6.1 ppm correspond to the vinyl protons on each of the two
methacrylate groups (58), confirming the successful functionalization of PEG. The area
under the integral for the vinyl protons was compared to that of the PEG backbone (δ =
3.5 ppm) and the methacrylation efficiency of the reaction was calculated to be
approximately 68.7%.
A representative 1H-NMR spectrum for PNIPAAm-PEG copolymers is shown in
Figure 4.2. The two distinctive peaks at δ = 3.5 ppm and δ = 3.6 ppm are characteristic
for the protons on the repeat unit of PEG, -(CH2CH2O)n-, and the CH protons adjacent to
the isopropyl group of NIPAAm, respectively (58, 102). The presence of these peaks
indicates that PEG was successfully incorporated along the backbone of PNIPAAm,
while the absence of the peaks for the vinyl protons on the double bond of the NIPAAm
monomer and/or PEG dimethacrylate (δ = 5.7 ppm, 6.1 ppm) confirms the removal of
excess reactants from the copolymer network. The relative amounts of NIPAAm and
PEG in the copolymer were quantified by comparing the area under the integral for the
peaks at δ =3.5 ppm and δ = 3.6 ppm; based on these calculations, all copolymers had
molar ratios satisfactorily close to the targeted compositions.
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4.3.2

Qualitative Assessment of PNIPAAm-PEG Cell Viability
The morphology of adherent human embryonic kidney (HEK) cells was observed

prior to incorporation into the polymer matrix, as shown in Figure 4.3, and the viability of
HEK cells within 10 wt% PNIPAAm-PEG was determined using a dual fluorescent stain
to distinguish between live and dead cells. On Day 0, HEK-seeded scaffolds were
immediately stained following hydrogel solidification at 37°C to confirm the presence of
viable cells within PNIPAAm-PEG at the time of incorporation. As can be seen in Figure
4.4, viable cells fluoresce green while dead cells fluoresce red. In contrast to the viable
cells, the day 0 stain indicates that relatively few dead cells were seeded within the
scaffold. Over days 6 – 25, the cells appear to remain healthy and proliferate, with
minimal cell death.

However, unlike the viable cells in Figure 4.3 that exhibit an

attached morphology in which the cell processes are extended, the HEK cells within
PNIPAAm-PEG express a rounded morphology and clustering. Although the scaffold
does not appear to be toxic to HEK cells, the cells remain unattached to the copolymer
after 25 days in vitro.

4.3.3

Quantitative Assessment of PNIPAAm-PEG Cell Viability
The viability of HEK cells within 10 wt% PNIPAAm-PEG was further assessed

using a quantifiable MTT cell proliferation assay. On day 0, HEK-seeded PNIPAAmPEG solutions were centrifuged to separate the matrix from the cells, and the cells were
assayed to quantify the initial seeding density. Figure 4.5 shows the optical density of the
cells, which is directly proportional to the cell concentration, over 18 days in vitro within
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PNIPAAm-PEG. The day 0 and 6 data represent the mean value of samples in triplicate,
while sample sizes of n = 2 and n = 1 were used for analysis on days 13 and 18,
respectively. These data indicate a significant increase (p < 0.05) in cell density with
PNIPAAm-PEG over 6 days in vitro.

4.3.4

RF-GFP Imaging
In addition to using a dual fluorescent stain to qualitatively assess the

cytocompatibility of PNIPAAm-PEG, cell proliferation was assessed via green
fluorescent protein (GFP) reporter gene expression in primary rat fibroblasts. The GFP
gene is maintained within the fibroblasts’ genome, and can be used as a marker to assess
proliferation from GFP-positive cells without additional staining. Fibroblasts expressing
GFP were cultured in 10 wt% PNIPAAm-PEG in vitro and imaged over 15 days. As
shown in Figure 4.6, the number of green-fluorescing fibroblasts appears to increase as
the cells are cultured within the scaffold, indicating that the cells are alive are
proliferating. Although this assay is limited to detection of only living cells and does not
provide insight to the number of dead cells, the continued proliferation of fibroblasts after
15 days in vitro supports the observations from the dual fluorescent assay.

4.4 Discussion

4.4.1

PNIPAAm-PEG – HEK Cytocompatibility
PNIPAAm-PEG copolymers were polymerized in a 600:1 molar ratio of

NIPAAm monomer units to PEG branches and characterized by 1H-NMR Spectroscopy.
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Cytocompatibility of the copolymers was assessed in vitro using a qualitative dual
florescent stain to detect viable and dead human embryonic kidney cells seeded within
PNIPAAm-PEG, as shown in Figure 4.4. All cells are labeled with SYTO® 10, a green
fluorescent nucleic acid stain that permeates the membranes of cells with both intact and
compromised plasma membranes. Dead cells are then distinguished from live cells using
DEAD RedTM, an impermeable red fluorescent nucleic acid stain that labels only cells
with damaged membranes. Based on these stains, HEK seeded within PNIPAAm-PEG
over 25 days in vitro appear viable; the increasing number of green-fluorescing cells is
indicative of cell survival and proliferation, and the limited and relatively constant
number of red-fluorescing cells suggests cell-scaffold cytocompatibility.
Despite these observations, the HEK do not exhibit an attached morphology after
25 days in suspension within PNIPAAm-PEG. This phenomenon may be attributed to
the PEG content and/or the formation of HEK clusters within the copolymer. It is
conceivable that the hydrophilic PEG chains within the hydrogel network sterically
hinder cell adhesion to the surface of PNIPAAm-PEG (2). However, PNIPAAm-PEG
hydrogels synthesized in a 700:1 molar ratio of NIPAAm monomer units to PEG units
were shown in prior work (47) to support the attachment of bone marrow-derived
mesenchymal stem cells after 14 days in vitro. Therefore, the inability of the cells to
attach to PNIPAAm-PEG scaffolds is more likely attributed to clustering of the HEK,
leading to aberrant phenotypic expression. It is possible that the rapid proliferation rate
of the cells resulted in high cell densities, causing the HEK to cluster (103).
Alternatively, HEK tend to detach from substrates when stored at temperatures below
37°C for any length of time. Since a fixative was not applied before observing and
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imaging the cells, it is possible that the HEK detached from the hydrogel during
processing at room temperature. However, these hypotheses were not confirmed in this
work.
In earlier studies, cell-seeded PNIPAAm-PEG hydrogels were also cryosectioned
after LIVE/DEAD staining to assess cell distribution within the scaffold.

Stained

samples were fixed in 4% Paraformaldehyde (PFA), flash frozen with dry ice and Nmethylbutane, and cryosectioned. The hydrogel slices were then transferred to gelatincoated slides and imaged. Consequently, this method yielded cell fragments within the
hydrogel and was ineffective in identifying distribution. Although not investigated in this
work, a more useful technique for depth selectivity and imaging within hydrogel samples
is confocal laser scanning microscopy (104). Instead of slicing the samples, confocal
images are acquired by optical sectioning, creating a representative image of sequentially
scanned sections of the hydrogel sample.

As a result, details of HEK distributed

throughout thick PNIPAAm-PEG samples can be imaged at various depths from the
hydrogel surface.
A quantitative MTT cell proliferation assay was performed to confirm the results
observed from the qualitative LIVE/DEAD analysis. The assay indirectly measures cell
growth via conversion of a water-soluble tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide), to an insoluble formazan as a result of mitochondrial
activity of the cells (105).

The formazan is subsequently solubilized and the

concentration is determined by measuring the optical density of the solution. In general,
mitochondrial activity is constant in viable cells; therefore, changes in formazan
concentration directly reflect increases or decreases in the cell population. As Figure 4.5
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shows, the results of the MTT assay support the findings of the dual fluorescent stain as
the optical density of the solution increases after suspension within PNIPAAm-PEG in
vitro over 18 days, indicating that the hydrogel is not cytotoxic to HEK.

4.4.2

PNIPAAm-PEG – Fibroblast Cytocompatibility
In addition to HEK, the viability of rat fibroblasts was assessed within

PNIPAAm-PEG scaffolds in vitro over 15 days.

The fibroblasts were modified to

express brain-derived neurotrophic factor (BDNF) and the green fluorescent protein
(GFP).

Although BDNF was not needed for this work, these cells were originally

isolated and modified for an in vivo study described elsewhere (78) and later provided for
the in vitro study described here for their GFP-expression. GFP, discovered from the
jellyfish Aequorea victoria, fluoresces spontaneously when exposed to oxygen and
enables the GFP-labeled cells to be imaged using fluorescent microscopy. Based on the
results in Figure 4.6, GFP-expressing fibroblasts within PNIPAAm-PEG continue to
proliferate as the number of green-fluorescing cells increases. However, the cells exhibit
a rounded morphology as opposed to the elongated structure normally expressed by
adherent fibroblasts, suggesting that the cells are not yet attached to PNIPAAm-PEG
hydrogels after 15 days in vitro. Nevertheless, recently published in vivo work (78) not
only demonstrates that PNIPAAm-PEG scaffolds can be used to deliver cellular grafts to
a spinal cord injury site and support cell survival, but also that the grafts remain within
the hydrogel post-implantation. Taken together, these results indicate that PNIPAAmPEG is a feasible scaffold for repair of the injured spinal cord.
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4.5 Conclusion
Thermoresponsive hydrogels composed of poly(N-isopropylacrylamide) with
polyethylene glycol graft chains were assessed for cytocompatibility using two cell lines,
human embryonic kidney cells (HEK) and green fluorescent protein-expressing rat
fibroblasts. Using a dual fluorescent LIVE/DEAD stain to distinguish between viable
and non-viable cells, viability and continued proliferation of HEK was demonstrated over
25 days of in vitro culture within PNIPAAm-PEG. The cytocompatibility of the hydrogel
scaffold was further confirmed through an MTT cell proliferation assay, which detected
an increase in mitochondrial activity of HEK within PNIPAAm-PEG over 18 days.
Similar findings were observed for fibroblasts cultured within the scaffold for 15 days.
Due to the fact that viability of these cells was measured based on GFP expression rather
than an assay requiring staining, non-specific staining of the hydrogel was avoided.
Taken together, these data indicate that PNIPAAm-PEG is not cytotoxic and merits
further evaluation in vivo for the treatment of SCI.
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‘
Figure 4.1 1H NMR Spectra of PEGDM in deuterium oxide at 25°C.
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Figure 4.2 1H NMR Spectra of PNIPAAm-PEG (1200:1 molar ratio) in deuterium oxide
at 25°C.

77

Figure 4.3 HEK cells (P.6) in culture prior to seeding with PNIPAAm-PEG.
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A. Day 0 20x Magnification

B. Day 6 5x Magnification

C. Day 13 5x Magnification

D. Day 18 5x Magnification

E. Day 25 5x Magnification
Figure 4.4 HEK LIVE/DEAD Viability/Cytotoxicity Assay.
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Figure 4.5 MTT Cell Proliferation Assay of HEK seeded within PNIPAAm-PEG (600:1
Molar Ratio NIPAAm:PEG).
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A. Day 1 5x Magnification

B. Day 1 10x Magnification

C. Day 5 5x Magnification

D. Day 5 10x Magnification

E. Day 15 5x Magnification

F. Day 15 10x Magnification

Figure 4.6 Fluorescent Microscopy imaging of GFP-expressing RF within PNIPAAmPEG.
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Chapter 5
Synthesis of PNIPAAm-CS Hydrogels
5.1 Introduction
In addition to spinal cord injuries, PNIPAAm-PEG has been proposed as a
candidate material for replacement of the nucleus pulposus and treatment of
intervertebral disc degeneration (58, 77). Disc degeneration generally stems from natural
physiological changes that occur within the disc over time, leading to dehydration of the
nucleus pulposus and impaired function of the disc (14, 16, 49, 50). The abnormal
compressive stress on the disc can subsequently lead to tearing of the annulus fibrosus,
allowing the nucleus to migrate and impinge on surrounding nerves (49, 58). Although
disc degeneration can be treated currently with major surgical intervention, most
commonly involving spinal fusion or total disc replacement, these approaches are aimed
at symptomatic relief rather than repair of the native tissue (55).
Recently, however, research has focused on cell-based tissue engineering
strategies, such as seeding cells within a 3-dimensional matrix to increase the viable cell
population in the disc and production of matrix components (68, 69, 73, 75). Still,
current scaffold designs have inherent drawbacks such as limited control over pore
interconnectivity, mechanical properties and degradation rates; other scaffold lack the
incorporation of biological components, useful in improving the biocompatibility of
synthetic materials, and may also require invasive procedures for implantation. Although
PNIPAAm-PEG exhibits many characteristics of a suitable scaffold for nucleus pulposus
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replacement, including: [1] biocompatibility, [2] in situ gel formation, [3] tunable
mechanical properties, [4] pore interconnectivity, [5] excellent mass and volume
retention, and [6] local delivery of growth factors, the synthetic scaffold lacks the
incorporation of biological components that enable enzymatic degradation. An ideal
scaffold replacing the nucleus pulposus would serve as only a temporary dynamic,
construct that can support the load-bearing requirements of the disc until new disc tissue
is formed.

This would require a biodegradable scaffold, which must degrade at a

controllable rate without compromising the mechanical stability of the surrounding
tissue.
Based on this precedence, and prior work with PNIPAAm-PEG, the goal of this
aim is to develop a family of biodegradable, thermoresponsive PNIPAAm-based
copolymers by polymerizing NIPAAm in the presence of methacrylated chondroitin
sulfate, a natural component of the intervertebral disc.

5.2 Experimental Section

5.2.1

Materials
N-isopropylacrylamide (NIPAAm) monomer was purchased from Sigma-Aldrich

(St. Louis, MO) and recrystallized in n-hexane before use. Chondroitin sulfate A (CS)
from bovine trachea and methacrylic anhydride (94%) were purchased from SigmaAldrich (St. Loius, MO) and used as received. The initiator ammonium persulfate (APS,
98%) and accelerator N,N,N’,N’-tetramethylethylene diamine (TEMED, 99%) were
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purchased from Fisher Scientific (Pittsburgh, PA) and used as received. All reagents
used were of analytical grade.

5.2.2

CS Methacrylation
Chondroitin sulfate A (CS) was methacrylated as described previously (100).

Briefly, CS was dissolved in DI water at a concentration of 25% (w/v) and heated to
60°C. The solution pH was adjusted to pH ~ 10 using aqueous sodium hydroxide, and
methacrylic anhydride was added dropwise to the solution in 3 different molar ratios of
methacrylic anhydride to CS: 25:1, 50:1, and 200:1. The solution was stirred vigorously
for 24 h at 60°C. Methacrylated CS was precipitated into cold methanol, isolated via
vacuum filtration and subsequently dried under vacuum and stored at -20°C until use.
The methacrylation efficiency of CS was determined by 1H-NMR (400 MHz Varian
Oxford AS400) in deuterium oxide at 25°C, and the area under the integral for the methyl
group on the vinyl bond (δ = 1.8 ppm) was compared to that of the acetyl methyl group
on the original CS (δ = 1.9 ppm) (94). The successful substitution of methacrylate
groups on CS was further confirmed by two distinctive peaks at δ = 5.7 ppm and δ = 6.1
ppm, assigned to the vinyl protons (C = CH2), which are not present in native CS.

5.2.3

PNIPAAm-CS Synthesis
Purified NIPAAm monomer and methacrylated CS were dissolved in DI water in

varying molar ratios (600:1 to 7000:1 NIPAAm to CS) to yield a concentration of 5 wt%
total monomer.

The monomer solutions were deoxygenated with nitrogen for

approximately 10 – 15 min, and the accelerator, TEMED, was added to the solutions at a
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concentration of 8% (v/w) of the total monomer amounts. The initiator, APS, was then
added to the solutions at a concentration of 0.8 wt% of the total monomer amounts, and
the solutions were stirred vigorously for 15 s and reacted at room temperature for 24 h
under fluorescent lighting. Following polymerization, the solutions were heated to 37°C
for gelation and the excess water and unreacted monomer were removed.

The

copolymers were freeze-dried, ground to a fine powder and purified as 10 wt% solutions
in deionized water, refreshing the water daily. Purified PNIPAAm-CS copolymers were
then freeze-dried and reground, and stored at 4°C until use.
The composition of PNIPAAm-CS hydrogels was assessed by 1H-NMR (400
MHz Varian Oxford AS400) in deuterium oxide at 25°C. The area of the peak at δ = 3.6
ppm, attributed to the CH protons adjacent to the isopropyl group of NIPAAm, was
compared to that of the peak at δ = 1.93 ppm, representative of the acetyl methyl group of
methacrylate-substituted CS. In addition, the absence of the vinyl protons on the double
bonds of NIPAAm and CS (δ = 5.7, 6.1 ppm) confirmed the removal of unreacted
monomer from the hydrogel.

5.3 Results and Discussion

5.3.1

Methacrylation of CS
The synthesis of methacrylate-substituted CS is illustrated in Figure 5.1. In the

presence of methacrylic anhydride, the hydroxyl groups on CS nucleophilically attack the
carbonyl groups of methacrylic anhydride through nucleophilic acyl substitution to yield
methacrylate-functionalized CS (94). A sample 1H NMR spectrum for methacrylate-
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substituted chondroitin sulfate can be seen in Figure 5.2. The presence of the sharp
singlets at δ = 5.7 and 6.1 ppm are attributed to the vinyl protons on the double bond of
methacrylated CS, indicating the successful substitution of methacrylate groups on CS.
The degree of substitution (DS) was calculated by comparing the areas of the two
distinctive peaks at δ = 1.8 and 1.9 ppm, corresponding to the methyl group on the vinyl
bond of methacrylated CS and the acetyl methyl group present on unmodified CS,
respectively (94). Based on these calculations, the 25:1, 50:1 and 200:1 molar ratios of
methacrylic anhydride to CS resulted in DS values of 0.1, 0.2 and an average of 0.6,
respectively. Since three hydroxyl groups are present on CS that can be methacrylated,
the maximum possible DS value for this reaction is equal to 3. A summary of the
methacrylate substitution reactions completed for this work is provided in Table 5.1.

5.3.2

Synthesis of PNIPAAm-CS Copolymers
For each methacrylated CS macromer, a family of PNIPAAm-CS copolymers was

synthesized by reacting NIPAAm monomer with methacrylated CS in molar ratios
ranging from 600:1 (high CS content) to 7000:1 (low CS content). A representative 1H
NMR spectrum for PNIPAAm-CS copolymers can be seen in Figure 5.3. Despite that the
acetyl protons of methacrylate-substituted CS have a characteristic signal at δ = 1.93
ppm, the chemical shift associated with the CH protons adjacent to the carbonyl group of
PNIPAAm results in an overlapping signal between δ = 1.8 and 2.0 ppm. As a result, the
relative composition of NIPAAm and CS in the copolymers is unclear. However, the
removal of excess reactants from the copolymer network is confirmed by the absence of
the peaks at δ = 5.7 and 6.1 ppm, representing the vinyl protons on the double bonds of
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the NIPAAm monomer and methacrylated CS macromer. An alternative method that
may overcome the limitations of 1H NMR is Fourier Transform Infrared Spectroscopy, or
FTIR. Unlike 1H NMR, in which the absorption of energy results in transitions between
nuclear spin levels that provides information about the number and type of hydrogen
atoms, the absorption of energy in FTIR causes covalent bonds to transition between
vibrational energy levels (106). In turn, FTIR can be used as a qualitative tool to identify
specific functional groups present in a molecule. Another approach that can be used to
quantify CS incorporation involves an assay using dimethylmethylene blue, or DMB,
which is a cationic dye that binds to sulfated glycosaminoglycans (93). Binding of DMB
to sulfate on mCS results in metachromatic changes in DMB that are subsequently
detected using standard spectrophotometric techniques.
The range of PNIPAAm-CS copolymer compositions produced in this work is
summarized in Table 5.2. The effect of CS incorporation on the lower critical solution
temperature (LCST) of the network can be seen in Figure 5.4, which compares high and
low contents of CS as well as varying degrees of methacrylate substitution.

The

thermoresponsive behavior of selected PNIPAAm-CS copolymers is shown at 25°C,
immediately post-polymerization, and at 37°C during purification as 10 wt% hydrogels in
excess deionized water. Copolymers prepared with high contents of CS (600:1 and
1000:1 NIPAAm to CS) and having the highest degree of methacrylate substitution (DS =
0.7) did not produce adequate gels.

In contrast, copolymers produced using

methacrylated chondroitin sulfate with DS = 0.5 formed solid hydrogels at 37°C. Based
on these observations, only copolymers prepared with CS having methacrylation degrees
of 0.1, 0.2 and 0.5 with sufficient NIPAAm content to yield solid gels were further
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characterized. Although not presented in this work, the effect of copolymer composition
on the thermal transition temperature of the hydrogel can be measured directly using
Differential Scanning Calorimetry, or DSC, which can be used to confirm that the phase
transition of the network occurs at or near physiological temperatures.

5.4 Conclusion
Chondroitin sulfate A was functionalized using methacrylic acid, and the extent of
methacrylate-substitution on CS was quantified using 1H NMR. Subsequently, a family
of thermoresponsive hydrogels was prepared by polymerizing N-isopropylacrylamide
(NIPAAm) in the presence of methacrylated CS (mCS), using varying molar ratios of
NIPAAm to mCS and varying degrees of methacrylate substitution on CS. Although the
relative compositions of the ensuing PNIPAAm-CS hydrogels were not quantifiable
using 1H NMR, the removal of excess reactants from the hydrogel was confirmed based
on the absence of the signal associated with the vinyl protons found in the NIPAAm
monomer and methacrylated CS macromer.

The effect of composition on the

thermoresponsive behavior of the hydrogels was observed visually by comparing the
hydrogels at room temperature post-reaction and at 37°C during purification. Increasing
the degree of methacrylate-substitution in hydrogels with high CS contents inhibited solid
gel formation, possibly due to steric hindrance of the PNIPAAm chains and
hydrophilicity of CS.

To gain a better understanding of this system, the trade-off

between the monomer molar ratios versus the degree of CS methacrylation is investigated
in the next chapter.
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Table 5.1 Degree of methacrylate substitution on CS. DS corresponds to the peak
intensity of the methyl group on the vinyl bond (δ = 1.8 ppm), absent in native CS,
relative to that of the acetyl methyl group of native CS (δ = 1.9 ppm).

Sample
mCS 1011
mCS 1009
mCS 1010
mCS 1012
mCS 1014
mCS 1008

Molar Ratio
Degree of Substitution
MAA:CS
(DS)
25:1
0.1
50:1
0.2
50:1
0.2
50:1
0.2
200:1
0.5
200:1
0.7
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Table 5.2 Compositions of PNIPAAm-CS copolymers produced.
Sample
PNIPAAm-mCS 1008-1
PNIPAAm-mCS 1008-2
PNIPAAm-mCS 1008-3
PNIPAAm-mCS 1008-4
PNIPAAm-mCS 1008-5
PNIPAAm-mCS 1008-6
PNIPAAm-mCS 1008-7

Molar Ratio
MA:CS
200
200
200
200
200
200
200

mCS Degree of
Substitution (DS)
0.7
0.7
0.7
0.7
0.7
0.7
0.7

Molar Ratio
NIPAAm:mCS
600
1000
1400
1800
2500
3000
4000

PNIPAAm-mCS 1014-5
PNIPAAm-mCS 1014-6
PNIPAAm-mCS 1014-7
PNIPAAm-mCS 1014-1
PNIPAAm-mCS 1014-2
PNIPAAm-mCS 1014-3
PNIPAAm-mCS 1014-4

200
200
200
200
200
200
200

0.5
0.5
0.5
0.5
0.5
0.5
0.5

600
1000
2000
4000
5000
6000
7000

PNIPAAm-mCS 1009-1
PNIPAAm-mCS 1009-2
PNIPAAm-mCS 1009-3
PNIPAAm-mCS 1009-4
PNIPAAm-mCS 1009-5
PNIPAAm-mCS 1009-6
PNIPAAm-mCS 1009-7

50
50
50
50
50
50
50

0.2
0.2
0.2
0.2
0.2
0.2
0.2

600
1000
1400
1800
2500
3000
4000

PNIPAAm-mCS 1010-5
PNIPAAm-mCS 1010-6
PNIPAAm-mCS 1010-1
PNIPAAm-mCS 1010-2
PNIPAAm-mCS 1010-3
PNIPAAm-mCS 1010-4

50
50
50
50
50
50

0.2
0.2
0.2
0.2
0.2
0.2

600
1000
1400
2000
3000
4000

PNIPAAm-mCS 1011-5
PNIPAAm-mCS 1011-6
PNIPAAm-mCS 1011-1
PNIPAAm-mCS 1011-2
PNIPAAm-mCS 1011-3
PNIPAAm-mCS 1011-4

25
25
25
25
25
25

0.1
0.1
0.1
0.1
0.1
0.1

600
1000
1400
2000
3000
4000

PNIPAAm
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Figure 5.1 Reaction scheme of methacrylate-substituted Chondroitin Sulfate.
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Figure 5.2 1H NMR Spectra of CS Methacrylation in deuterium oxide at 25°C, DS = 0.2.
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Figure 5.3 1H NMR Spectra of PNIPAAm-CS in deuterium oxide at 25°C.
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25°C

37°C

Low CS
Content

DS: 0.2

High CS
Content

Low CS
Content

DS: 0.7

High CS
Content

Figure 5.4 Thermoresponsive behavior of PNIPAAm-CS copolymers. (Left) Solutions,
at 25°C, post-reaction. (Right) Gel formation at 37°C; images taken during purification
of 10 wt% hydrogels in excess deionized water.
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Chapter 6
Characterization of PNIPAAm-CS Hydrogels
6.1 Introduction
In the previous chapter, a family of thermoresponsive copolymers was produced
from N-isopropylacrylamide and methacrylated chondroitin sulfate and analyzed by 1H
NMR. However, to better understand the potential of these copolymers as candidate
materials for nucleus pulposus replacement, further characterization of the hydrogels is
needed. The aim of this chapter is to examine the effect of copolymer composition on the
hydrogel properties. More specifically, the water content, mass retention and elasticity of
the hydrogels are quantified as a function of CS content and degree of methacrylate
substitution.

6.2 Experimental Section

6.2.1

PNIPAAm-CS Swelling Studies
The swelling behavior of PNIPAAm-CS hydrogels with varying degrees of CS

methacrylation (0.1 – 0.5) and varying molar ratios of NIPAAm to CS (600:1 – 7000:1)
was characterized, and compared to that of PNIPAAm homopolymer. PNIPAAm-CS
copolymers were dissolved in 0.01 M Dulbecco’s Phosphate Buffered Saline (PBS) at a
concentration of 5 wt%, yielding solutions with minimal viscosity that enable gel
formation at physiological temperature. Approximately 1 mL of each copolymer solution
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was transferred to pre-weighed glass vials and the initial wet mass was measured. The
solutions were heated to 37°C to form hydrogel discs and subsequently immersed in 5
mL of 0.01 M PBS for 14 days to achieve swelling equilibrium. Excess PBS was then
removed from the vials and the final wet mass of the discs was measured. Post-swelling,
the samples were freeze-dried and the dry mass was measured. A sample size of n = 6
was used for each PNIPAAm-CS composition. For each PNIPAAm-CS solution, the
initial copolymer concentration was determined by freeze-drying a set of samples on Day
0, prior to swelling at 37°C. The water content of the swollen gels at equilibrium was
calculated according to Equation 6.1, where mwet,37°C(t) and mdry(t) refer to the wet gel
mass at 37°C and dry mass, respectively, at time t.

𝑊𝑎𝑡𝑒𝑟  𝑐𝑜𝑛𝑡𝑒𝑛𝑡   % =    1 −

𝑚𝑑𝑟𝑦 (𝑡)
𝑚𝑤𝑒𝑡,37°C (𝑡)

Equation 6.1

×100

In addition, the mass retention of the hydrogels was calculated according to Equation 6.2,
where mwet,25°C(t = 0) refers to the mass of the copolymer solution initially placed in the
vial at 25°C on day 0 and C refers to the copolymer concentration, calculated based on
the day 0 wet and dry masses.

𝑀𝑎𝑠𝑠  𝑅𝑒𝑡𝑒𝑛𝑡𝑖𝑜𝑛  (%) =   

𝑚𝑑𝑟𝑦 (𝑡)
𝐶  ×  𝑚𝑤𝑒𝑡,25°𝐶 (𝑡 = 0)
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×100

Equation 6.2

6.2.2

PNIPAAm-CS Compressive Studies
The equilibrium compressive moduli for the family of PNIPAAm-CS hydrogels

were determined from unconfined uniaxial compression tests.

PNIPAAm-CS

copolymers were dissolved in 0.01 M PBS at a concentration of 5 wt%. Approximately
10 mL of each solution was centrifuged at 1500 rpm for 15 – 20 min, to remove
entrapped air, and subsequently gelled at 37°C. The hydrogels were transferred to a 37°C
PBS bath and sliced into small discs, which were then stored in a glass vial containing
0.01 M PBS at 37°C for 14 days to reach equilibrium swelling. Equilibrated gels were
loaded in a Shimpo mechanical testing system and compressed to 30% strain at a rate of
10 mm/min, while submerged in a 37°C PBS bath. Load and displacement data were
recorded and used to calculate stress and strain values. The equilibrium compressive
modulus at 15% strain was approximated as the slope of the chord between 10% and 20%
strain. A sample size of n ≥ 3 was used for all PNIPAAm-CS compositions studied.
PNIPAAm homopolymer was used as a control.

6.2.3

Statistical Analysis
Data were analyzed using one and two way analysis of variance (ANOVA) with a

95% confidence level. Post-ANOVA pair-wise comparisons of groups with significant
interactions and equal variances were made using Tukey’s HSD post-hoc tests; groups
with unequal variances were compared using Games-Howell post-hoc tests.

97

6.3 Results

6.3.1

Equilibrium Swelling of PNIPAAm-CS
The effect of CS incorporation on the in vitro swelling properties of PNIPAAm at

37°C can be seen in Figure 6.1, which compares the swelling of PNIPAAm-CS (2500:1
NIPAAm to CS, DS = 0.2) to that of PNIPAAm homopolymer. Unlike the hydrophobic
and inelastic PNIPAAm network, the copolymer results in significant swelling of the
hydrogel and exhibits higher elasticity.
To quantify these observations, the water content of PNIPAAm-CS copolymers
swollen over 14 days in vitro was calculated and can be seen in Figure 6.2. The degree of
methacrylate substitution and molar ratio of the copolymers have overall significant
effects on the water content of the resulting copolymers (p < 0.05). The interaction of the
two variables is also statistically significant at the 95% confidence level. Increasing the
degree of methacrylate substitution on CS before copolymerization with NIPAAm results
in overall decreases in the water content of the hydrogels. In contrast, PNIPAAm-CS
hydrogels exhibit significant increases in water content as the amount of CS incorporated
into the copolymers during copolymerization increases from a molar ratio of 4000:1 to
600:1 NIPAAm to CS. However, only PNIPAAm-CS produced with a DS of 0.2 and a
600:1 molar ratio of NIPAAm to CS resulted in a statistically significant increase in
water content relative to the PNIPAAm homopolymer control.
The effect of varying the CS content of the copolymers is further demonstrated in
Figure 6.3, which shows the water content for each degree of methacrylate substitution
tested, over the range of copolymer compositions produced. For all three ratios of
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methacrylate substitution, hydrogels produced at a 4000:1 molar ratio of NIPAAm to CS
exhibit significant reductions in water content relative to copolymerization at a 600:1
molar ratio. There is no further loss in water content when the molar ratio is reduced
from 4000:1 to 6000:1 or 7000:1 (p > 0.05) using the highest degree of methacrylatesubstituted CS.

6.3.2

Mass Retention of PNIPAAm-CS
The data presented in Figure 6.4 show that the degree of methacrylate substitution

and molar ratio of NIPAAm to CS have significant effects on the mass retention of
PNIPAAm-CS hydrogels after immersion in PBS over 14 days. By and large, over the
range of NIPAAm to CS molar ratios tested, hydrogels containing CS with a
methacrylation degree equal to 0.2 exhibit significant mass losses relative to those with
CS methacrylate substitution ratios of 0.1 and 0.5. Hydrogels produced with the lowest
contents of the most methacrylated CS macromer (4000:1 NIPAAm to CS, DS: 0.5),
result in the highest mass retention, 82.89 ± 0.7%. Excluding PNIPAAm-CS with a
600:1 NIPAAm to CS molar ratio and 0.2 degree of methacrylation, all hydrogels
produced retained significantly more mass than PNIPAAm homopolymer after 14 days
immersion in vitro. The effect of varying the composition of PNIPAAm-CS while
holding DS constant can be seen further in Figure 6.5, which shows that hydrogels
exhibit a significant increase in mass retention as the CS content within PNIPAAm-CS is
reduced, for all degrees of methacrylation investigated (p < 0.05).
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6.3.3

Compressive Mechanical Studies of PNIPAAm-CS
The compressive moduli for PNIPAAm-CS copolymers were determined after 14

days immersion in vitro at 37°C. Sample stress-strain curves for hydrogels tested in
unconfined compression in PBS at 37°C are provided in Figure 6.6; the curves shown
represent data collected for PNIPAAm-CS hydrogels prepared at a 2000:1 NIPAAm to
CS molar ratio and 0.5 degree of methacrylate substitution. The compressive moduli for
all PNIPAAm-CS hydrogels, calculated at 15% strain, are shown in Figure 6.7.
Increasing the degree of methacrylation on CS prior to polymerization with NIPAAm
significantly reduces the elasticity of the hydrogels; these differences are most drastic
between DS 0.1 and DS 0.5. The data in Figure 6.8 further compare the effect of varying
the NIPAAm to CS molar ratio while holding DS constant.

As the figure shows,

increasing the molar ratio of NIPAAm to CS during polymerization increases the
compressive moduli, or stiffness, of the hydrogels over the range of methacrylate
substitution degrees tested. As a result, PNIPAAm-CS hydrogels produced using a 600:1
molar ratio and low degrees of methacrylate substitution exhibit the highest elasticity,
while those produced using a 400:1 molar ratio and high degrees of methacrylate
substitution display the highest stiffness. For PNIPAAm-CS produced at a constant DS
of 0.2, increasing the molar ratio of NIPAAm to CS beyond 2000:1 does not significantly
change the elasticity of the hydrogels (p > 0.05). In addition, hydrogels produced at a
constant DS of 0.5 exhibit slight decreases in stiffness beyond a 5000:1 NIPAAm to CS
molar ratio; however, these differences are not significant at the 95% confidence level.
PNIPAAm-CS hydrogels at this DS also exhibit higher compressive moduli than the
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PNIPAAm homopolymer control, but it is unknown whether the stiffness of PNIPAAm is
statistically different than the PNIPAAm-CS copolymers investigated.

6.4 Discussion
In contrast to the hydrophobic and inelastic behavior of PNIPAAm homopolymer,
PNIPAAm-CS hydrogels can exhibit soft, tissue-like properties due to the water-binding
capacity of CS. As a sulfated glycosaminoglycan, CS contains both ionic carboxyl and
sulfate radicals that attract water electrically. Evidently, the density of these radicals can
be shown to be proportional to the water-binding capacity of the CS chains (10). Hence,
the water content of PNIPAAm-CS hydrogels is predominantly a function of the
concentration of chondroitin sulfate within the network. This is apparent in Figure 6.1,
which illustrates the pronounced differences between the water-binding capacities of
PNIPAAm and PNIPAAm-CS at 37°C.

While the homopolymer transitions to a

shrunken, hydrophobic state above the LCST, incorporation of CS into the network
enables water-polymer interactions between the carboxyl and sulfate radicals of the
glycosaminoglycan chains and subsequent hydration of PNIPAAm-CS. This is apparent
in Figures 6.2 and 6.3. As the concentration of CS chains within the network increases
while holding the CS degree of methacrylate-substitution constant, the water-binding
capacity of the PNIPAAm-CS hydrogel increases. In contrast, increasing the degree of
substitution on CS from 0.1 to 0.5 yields hydrogels with reduced water retention. This
can be attributed to an increase in hydrogen bond formation between the PNIPAAm and
mCS chains, as previously reported (98). Moreover, since there are three hydroxyl
groups within CS that can be substituted with methacrylate groups, increasing the molar
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ratio of methacrylic anhydride to CS yields macromer chains with a higher percentage of
methacrylate groups. In turn, these functional groups cause an increase in physical
entanglement among the chains of the PNIPAAm-CS network, reducing the ability of the
hydrogel to swell and retain water.
Consequently, changing the concentration of CS and degree of methacrylate
substitution within PNIPAAm-CS has similar effects on the compressive moduli of the
hydrogels. Hydrogels produced with the lowest molar ratios of NIPAAm to mCS exhibit
the lowest stiffness as a result of the hydrophilicity of CS. In this system, water acts as a
plasticizer that interferes with secondary interactions between the network chains,
thereby increasing the flexibility of the chains and reducing the compressive modulus
(58, 60). Alternatively, by increasing the degree of methacrylate substitution on CS the
PNIPAAm-CS chains become more physically entangled and less flexible; as a result, the
hydrogels exhibit higher compressive moduli, or stiffness, as DS is increased from 0.1 to
0.5. These findings are consistent with other studies of chondroitin sulfate-based and
natural hydrogels (100, 107) and are comparable to the properties of native NP, which
exhibits an average linear modulus of approximately 5.4 – 5.8 kPa (108, 109). Notably,
these data demonstrate that PNIPAAm-CS hydrogels can be tailored to mimic the
properties of native tissue.
Although the PNIPAAm-CS family of copolymers studied in this work display in
vitro mass loss after 14 days at 37°C, it is conceivable that this behavior is a result of
diffusion of unreacted monomer and macromer chains. As Figure 6.5 shows, increasing
the concentration of methacrylate-substituted CS within the network by using lower
molar ratios of NIPAAm to mCS reduces the mass retention of PNIPAAm-CS. Again,
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these data are consistent with the water-binding properties of CS, which increase
hydrogel swelling and can facilitate disentanglement of the network chains and
consequent diffusion of unbound chains.

To better understand the stability of

PNIPAAm-CS copolymers in the future, the hydrogels can be immersed in PBS in vitro
over extended periods of time after equilibrium mass retention is achieved; subsequent
changes in dry copolymer mass would then be attributed to poor stability rather than
diffusion of unreacted components. This method has been used in prior work to assess
the stability of PNIPAAm-PEG based copolymers (58, 77).

6.5 Conclusion
The effects of copolymer composition and degree of CS methacrylate substitution
on the swelling and mechanical properties of PNIPAAm-CS copolymers were
investigated. Copolymers produced with decreasing molar ratios of NIPAAm to mCS
exhibited higher water contents and reduced compressive moduli due to the water binding
capacity of the sulfated glycosaminoglycan. In contrast, as the degree of methacrylate
substitution on CS was varied from 0.1 to 0.5, an overall reduction in water content and
increase in modulus was observed. In this case, the functionality of CS reduces the
flexibility of the PNIPAAm-CS chains and increases physical entanglement of the
network.
In general, these data demonstrate that injectable, thermoresponsive PNIPAAmCS copolymers can be easily tailored to achieve a range of swelling and elastic properties
that mimic those of native nucleus pulposus tissue. As a result, this family of copolymers
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will be further assessed for in vitro biocompatibility and degradation to determine its
potential as a candidate material for nucleus pulposus regeneration.
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Day 1

Day 3

Day 7

Day 10

PNIPAAm-CS (DS: 0.2, MR 2500:1)

PNIPAAm Homopolymer

Figure 6.1 Effect of CS incorporation: Swelling of PNIPAAm-CS and PNIPAAm
homopolymer over 10 days at 37°C.
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Figure 6.2 Effect of composition on swelling behavior of PNIPAAm-CS.
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Figure 6.3 Effect of chondroitin sulfate degree of methacrylate substitution (DS) on the
swelling behavior of PNIPAAm-CS copolymers.
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Figure 6.4 In vitro mass retention of PNIPAAm-CS copolymers after 14 days at 37°C;
hydrogels prepared in PBS.

108

Figure 6.5 Effect of composition on mass retention of PNIPAAm-CS copolymers.
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Figure 6.6 Representative stress-strain curves for PNIPAAm-CS copolymers tested in
uniaxial unconfined compression in PBS at 37°C (DS = 0.5, 2000:1 Molar Ratio
NIPAAm:mCS).
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Figure 6.7 Effect of composition on PNIPAAm-CS modulus of elasticity.
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Figure 6.8 Effect of chondroitin sulfate degree of methacrylate substitution (DS) on the
elasticity of PNIPAAm-CS copolymers.
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Chapter 7
Evaluation of PNIPAAm-CS Scaffolds for Intervertebral Disc Repair
7.1 Introduction
In the field of tissue engineering, the overall goal is to develop materials that can
be implanted in the body to interact with the biological environment and restore the
function of natural living tissues (2, 60). Ideally, the biomaterial mimics the properties of
the native tissue being replaced or repaired. Within the nucleus pulposus of healthy
intervertebral discs, extracellular matrix (ECM) provides mechanical and structural
stability to the tissue, and continuously remodels the microenvironment in response to
tissue processes (79). An ideal tissue-engineered replacement for the nucleus pulposus
should serve as a temporary, biodegradable support to the surrounding disc tissue as the
native nucleus pulposus is regenerated.

This requires the degradation rate of the

biomaterial to be controllable to avoid premature structural breakdown and loss of
functionality. One way to achieve controlled degradation of polymeric biomaterials is to
incorporate naturally derived materials into the network. Natural polymers, such as
chondroitin sulfate (CS), usually undergo enzymatically-induced cleavage, and do not
result in toxic degradation products. By incorporating varying amounts of CS along the
backbone of PNIPAAm-based copolymers, the scaffold can be designed to degrade in
response to the actions of specific enzymes, such as chondroitinase, and the degradation
rate can be tailored.
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In addition to bulk material properties, the success of any biomaterial is highly
dependent on the biological response elicited within the host tissue.

Generally,

implantation of a biomaterial will stimulate an immediate, but temporary, inflammatory
reaction and possible activation of the immune system. Although these responses may
not be desirable, certain reactions are considered acceptable and will vary depending on
the application (2). The first step in understanding the biocompatibility of a biomaterial
is to characterize the cellular response to the material. It is important that the biomaterial
supports all required functions of the cell, including but not limited to viability and
proliferation, migration, activation and/or differentiation, communication and protein
synthesis (2). At the most basic level, cell-material interactions can be assessed via in
vitro cytotoxicity assays, which are often a required first step in biocompatibility testing.
In this aim, the degradation of PNIPAAm-CS is characterized in vitro over 7
days in the presence of chondroitinase ABC, an enzyme that catalyzes the degradation of
glycosaminoglycans such as CS. In addition, the interaction of human mesenchymal
stem cells (hMSC) seeded within PNIPAAm-CS is qualitatively assessed in vitro at 37°C,
and cell proliferation is determined over 21 days.

7.2 Experimental Section

7.2.1

Materials
Chondroitinase ABC was purchased from Sigma Aldrich (St. Louis, MO) and

reconstituted in 0.01% Bovine Serum Albumin (BSA) (Sigma Aldrich, St. Louis, MO) in
Phosphate Buffered Saline (PBS) at a concentration of 6.6x10-3 units/mL. Aliquots of
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enzymatic solution were stored at -20°C until needed to maintain chondroitinase ABC
activity.

7.2.2

In Vitro Enzymatic Degradation of PNIPAAm-CS
The enzymatic degradation of two PNIPAAm-CS hydrogels was investigated

using chondroitinase ABC. CS was methacrylate-substituted as described previously,
using a 200 to 1 molar ratio of methacrylic anhydride to CS, yielding CS with a degree of
substitution equal to 0.5. Purified NIPAAm monomer was reacted with methacrylated
CS in 600 to 1 (high CS content) and 7000 to 1 (low CS content) molar ratios using the
procedure outlined earlier. Solutions containing 5 wt% PNIPAAm-CS in 0.01 M PBS
were prepared, and approximately 1 mL of each copolymer solution, was transferred to
pre-weighed glass vials and heated to 37°C to form hydrogel discs. The discs were
subsequently immersed in 4 mL of chondroitinase ABC over 7 days, replacing the
enzyme solutions daily for maximum activity. At timed intervals, the enzymatic solution
was removed from PNIPAAm-CS samples (n = 3) and the wet masses of the gels were
measured. The samples were then flash frozen on dry ice, freeze-dried and the dry
masses of the enzyme-treated discs were measured. For each copolymer composition,
hydrogel discs were prepared on Day 0, in triplicate, and immediately frozen and
lyophilized to determine the average initial concentration of the untreated copolymer.
These data were used to calculate the theoretical dry mass, mdry,theoretical, of each sample
according to Equation 7.1, where mwet,37°C represents the wet mass of enzyme-treated
copolymer, at 37°C and Cinitial is the average initial copolymer concentration.
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𝑚!"#,!!!"#!$%&'(    𝑔 =    𝑚𝑤𝑒𝑡,37°C 𝐶𝑖𝑛𝑖𝑡𝑖𝑎𝑙

Equation 7.1

The average mass loss for each set of samples was calculated using Equation 7.2, where
mdry, actual is the measured dry mass of enzyme-treated copolymer.

𝑀𝑎𝑠𝑠  𝑙𝑜𝑠𝑠   % =    1 −

𝑚𝑑𝑟𝑦,𝑎𝑐𝑡𝑢𝑎𝑙
𝑚𝑑𝑟𝑦,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙

×100

Equation 7.2

As a control, the enzymatic mass loss after 7 days of immersion in chondroitinase ABC
in vitro was compared to the mass loss associated with 14 days of immersion in PBS.

7.2.3

In Vitro Cell Viability of PNIPAAm-CS Scaffolds
The biocompatibility of PNIPAAm-CS scaffolds was assessed using a

CellTraceTM CFSE Cell Proliferation assay (Molecular Probes, Invitrogen, Eugene, OR),
which contains the non-fluorescent cell-tracing reagent carboxyfluorescein diacetate,
succinimidyl ester (CFSE). CFSE diffuses into cells and is cleaved by intracellular
esterases, yielding a highly fluorescent carboxyfluorescein succinimidyl ester that
consequently forms fluorescent conjugates with intracellular amines.

In this work,

human mesenchymal stem cells (hMSC) were labeled with CellTraceTM CFSE and
proliferation was visualized by fluorescent microscopy.
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7.2.3.1 Preparation of PNIPAAm-CS Hydrogels
PNIPAAm-CS copolymers were prepared and purified as outlined previously. A
solution containing 8 wt% PNIPAAm-CS was prepared from the ground copolymer and
Minimum Essential Medium alpha (MEM-α) (Gibco, Invitrogen, Frederick, MD),
containing 20% Fetal Bovine Serum (FBS) (HyClone Laboratories, Inc., Logan, UT).
The PNIPAAm-CS solution was vortexed, stored at 4°C overnight for complete
dissolution, and steam-sterilized prior to use.

7.2.3.2 Human Mesenchymal Stem Cell Culture
Human adult bone marrow-derived mesenchymal stem cells (hMSC) were
harvested from volunteers, cultured and donated for use by Dr. Wolfe, Tulane Center for
Gene Therapy. Cryopreserved hMSC (2x106 hMSC, P.4) were thawed quickly at 37°C
and diluted in MEM-α (Gibco, Invitrogen, Frederick, MD) medium supplemented with
20% FBS (HyClone Laboratories, Inc., Logan, UT), 1% Antibiotic-Antimycotic (AntiAnti) Solution (Cellgro, Mediatech, Inc., Manassas, VA) and 2 mM L-glutamine. The
cells were centrifuged at 1000 rpm for 6 min and resuspended in MEM-α culture
medium. The cell suspension was plated (P.5) on sterile petri dishes and incubated in a
water-jacketed CO2 incubator at 37°C and 5% CO2 overnight, allowing for cell
attachment. The following day, the culture medium was replaced to ensure complete
removal of residual dimethyl sulfoxide (DMSO) freezing medium, and the cells were
cultured until 70-80% confluent. The cells were then washed with PBS and detached
from the culture plates using 0.1% trypsin Ethylenediaminetetraacetic Acid (EDTA)
solution. Detached hMSC were stained with trypan blue, which selectively colors non-
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viable cells, and counted using a hemacytometer. hMSC were routinely subcultured at a
split ratio of 1:2 in MEM-α culture media.

7.2.3.3 PNIPAAm-CS Cytocompatibility with hMSC
Roughly 4.9x106 viable hMSC (P.12) were suspended in 5 mL MEM-α culture
media and approximately 0.4 mL of the cell suspension was added to the PNIPAAm-CS
solution and mixed gently, yielding a 5 wt% copolymer solution seeded with an estimated
4.0x105 hMSC. As a control, a 2 wt% PNIPAAm homopolymer solution was prepared
and seeded with approximately 1.1x106 cells.

The copolymer- and polymer-cell

suspensions were each transferred to 3 wells of a 24-well tissue culture plate
(300_µL/well), and the hMSC-seeded scaffolds were incubated at 37°C and 5% CO2 for
30 min. Following complete solidification of the scaffolds, the gels were covered with
excess MEM-α culture media and incubated until analysis, refreshing the media
regularly.
At days 3, 7 and 21, the hMSC-seeded scaffolds were labeled for analysis,
according to the manufacturer’s protocol. The samples were transferred to sterile 35 mmpetri dishes, using aseptic technique, and excess media was replaced with 4 mL of 5 mM
CellTraceTM CFSE stock solution. The samples were incubated, at 37°C and 5% CO2, in
CFSE solution for 15 min and in 4 mL MEM-α culture media for an additional 30 min.
Post-incubation, excess media was aspirated. The scaffolds were washed in PBS, fixed
using 4% Paraformaldehyde (PFA) and imaged on glass slides using fluorescence
microscopy (Leica DM 5500B, Leica Microsystems, Bannockburn, IL) with Slidebook

118

software (Intelligent Imaging Innovations, Denver, CO) to determine cell proliferation
and viability.

7.2.4

Statistical Analysis
Samples from enzymatic degradation studies were analyzed using mixed analysis

of variance (ANOVA), with time as the repeated measure. Pairwise comparisons were
made for groups with significant interactions and equal variances using two-tailed t-tests.
One-way ANOVA tests were also conducted to identify significant mass losses within
each copolymer composition; pair-wise comparisons of groups with significant
interactions and equal variances were made using Tukey’s post-hoc tests and groups with
unequal variances were compared using Games-Howell post-hoc tests. For all analyses, a
95% confidence level was used.

7.3 Results

7.3.1

Enzymatic Degradation of PNIPAAm-CS
PNIPAAm-CS mass losses resulting from 7 days immersion at 37°C in vitro, in

enzymatic solution containing chondroitinase ABC, are shown in FIGURE 7.1. The
effect of high (600:1) and low (2000:1) CS content on copolymer degradation is
compared at four time intervals: 16 h, 22 h, 3 days and 7 days. By day 7, PNIPAAm-CS
copolymers produced with a 600:1 molar ratio were indistinguishable from the enzymatic
solution; as a result, mass loss was assumed to be 100% for the purpose of analysis.
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Overall, NIPAAm to CS molar ratio has a significant effect on PNIPAAm-CS
mass loss (p < 0.05). Copolymers produced at a 600:1 NIPAAm to CS molar ratio
generally result in higher average mass losses after 7 days in vitro than those produced
using a 2000:1 molar ratio. After 16 h, PNIPAAm-CS produced with 600:1 and 2000:1
molar ratios of NIPAAm to CS exhibit mass losses equal to 18.75% ± 1.16% and 15.73%
± 0.13%, respectively. After 3 days immersion with chondroitinase, mass losses of
27.96% ± 1.30% and 16.95% ± 0.88% are observed, respectively. In both cases, these
differences are statistically significant (p < 0.05). Significant differences within each
PNIPAAm-CS composition are also shown in Figure 7.1. For both molar ratios, a
significant increase in mass loss is observed between 16 h and 7 days immersion in vitro
and between days 3 and 7. In contrast, immersion in PBS for 14 days results in 23.89% ±
1.34% and 21.25% ± 0.42% mass losses from PNIPAAm-CS produced with 600:1 and
2000:1 molar ratios of NIPAAm to CS, respectively (Figure 6.4). These results confirm
that the mass losses observed for PNIPAAm-CS having high CS content are
predominantly due to the actions of chondroitinase ABC.
The effect of CS content within PNIPAAm-CS on the enzymatic degradation by
chondroitinase is further illustrated in Figure 7.2. After 7 days immersion in vitro at
37°C, PNIPAAm-CS produced with a 2000:1 NIPAAm:CS molar ratio exhibits an
opaque and solid disc structure; whereas, the 600:1 molar ratio copolymer appears
translucent with limited distinction between the remaining mass and enzymatic solution.
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7.3.2

Cytocompatibility of PNIPAAm-CS
The morphology of human mesenchymal stem cells (hMSC) was observed prior

to seeding within the copolymer matrix.

As shown in Figure 7.3, hMSC

characteristically express a flattened morphology with thin, extended processes. On day
0, hMSC were detached and seeded within 5 wt% PNIPAAm-CS (600:1 molar ratio
NIPAAm to CS, DS = 0.5), and cytocompatibility was investigated over 21 days in vitro.
Cell proliferation was assessed at days 3, 7 and 21 using a qualitative CellTrace CFSE
assay. The assay contains carboxyfluorescein diacetate succinimidyl ester (CFSE), a
non-fluorescent cell-tracing dye that diffuses into cells and reacts to yield a highly
fluorescent label, which is inherited by daughter cells. As shown in Figure 7.4, hMSC
stained by CFSE fluoresce green. Although this assay does not distinguish between live
and dead cells, the number of hMSC within PNIPAAm-CS appears to increase between
days 14 and 21, and is comparable to the proliferation observed within the homopolymer
control. In both cases, hMSC are dispersed throughout the scaffold. However, the cells
do not exhibit a morphology characteristic of adherent cells, suggesting that the hMSC
are unattached after 21 days in vitro.

7.4 Discussion
The overall aim of tissue engineering is to develop strategies to regenerate living
tissues with structural and biochemical similarity to the native host tissue such that
functional restoration can be realized (110). Since these constructs are intended to
interface with biological systems, biocompatibility of the material must be demonstrated.
As a general first step, this is achieved by measuring cytotoxicity with in vitro assays,
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such as the CFSE cell proliferation assay described here. As cells that can differentiate
into cartilage cells, or chondrocytes, which are responsible for maintaining homeostasis
within intervertebral discs, human mesenchymal stem cells (hMSC) represent a suitable
and clinically relevant cell line to measure PNIPAAm-CS biocompatibility.
Since PNIPAAm-CS is an injectable, thermoresponsive scaffold, hMSC can be
uniformly dispersed throughout the matrix prior to the phase transition of the hydrogel
under physiological conditions. In addition to tolerating this transition, the presence of
fluorescently labeled hMSC within the scaffold after 14 and 21 days in vitro
demonstrates that PNIPAAm-CS supports cell survival. Indeed, comparison with the
PNIPAAm control reveals that the cytocompatibility of PNIPAAm-CS is comparable to
that of the homopolymer. However, these results are expected since PNIPAAm-based
copolymers have been shown to display excellent biocompatibility both in vitro using
hMSC (47, 111) and in vivo using rat fibroblasts (78), and chondroitin sulfate is a
naturally derived biomaterial common to nucleus pulposus tissue. Still, it should be
noted that the CFSE assay is limited to detection of only living cells; therefore, additional
studies and proper controls are needed to better understand the cell-scaffold interactions
and how these interactions affect regeneration of the nucleus pulposus tissue.

For

instance, the differentiation of hMSC into active chondrocytes should be confirmed, in
addition to the degree of cell adhesion and migration supported by PNIPAAm-CS.
Given that the extracellular matrix is continually remodeled in vivo (2), an ideal
candidate nucleus pulposus replacement would exhibit biodegradability to facilitate new
tissue formation while providing temporary mechanical stability to the surrounding area.
Incorporation of natural chondroitin sulfate along the backbone of PNIPAAm enables the
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scaffold to be biologically degraded in vivo in the presence of chondroitinase ABC,
which catalyzes the eliminative degradation of CS. Moreover, the relative concentration
of synthetic and natural polymer chains within the network can be modified in order to
control and achieve a suitable enzymatic degradation rate. Importantly, the resulting
degradation products of PNIPAAm-CS are not expected to elicit an adverse inflammatory
response, although this remains to be confirmed.

In addition to understanding the

biological and cellular response to PNIPAAm-CS scaffolds, the mechanical stability of
PNIPAAm-CS hydrogels undergoing enzymatic degradation remains to be characterized;
this is to ensure that the function of the scaffold and stability of the surrounding
environment are not comprised during the tissue regeneration process. In conjunction,
the ability of PNIPAAm-CS to promote and support new tissue formation and integration
should be investigated to confirm the potential of the scaffold to aid in nucleus pulposus
repair and regeneration.

7.5 Conclusion
In this aim, the biocompatibility of a PNIPAAm-CS scaffold with high
chondroitin sulfate content was assessed and compared to that of its synthetic
counterpart, PNIPAAm homopolymer.

After 21 days of in vitro culture within

PNIPAAm-CS, human mesenchymal stem cells, which can differentiate into cartilagespecific cells known as chondrocytes, were viable and appeared to proliferate. However,
the morphology displayed by the cells suggests that the hMSC did not adhere to the
scaffold surface. Therefore, future work is needed to confirm that the interactions with
PNIPAAm-CS do not suppress the activity or functions of hMSC. As expected, the
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incorporation of a natural chondroitin sulfate macromer facilitated biodegradation of the
PNIPAAm-based copolymer in the presence of chondroitinase ABC.

Although the

degradation kinetics were not characterized in this work, comparison of PNIPAAm-CS
with high and low CS content suggests that the rate of degradation is controllable by
altering the scaffold composition.
Taken together, these studies show that PNIPAAm-CS can be used as a threedimensional temporary support for cell survival and proliferation to facilitate nucleus
pulposus tissue regeneration.
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Figure 7.1 Enzymatic degradation of PNIPAAm-CS, comparing high (600:1 molar ratio)
and low contents (2000:1 molar ratio) of CS within PNIPAAm-CS (DS = 0.5) in the
presence of chondroitinase ABC.
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(A) DS 0.5, MR 2000:1

(B) DS 0.5, MR 600:1

Figure 7.2 Representative enzymatic degradation images of PNIPAAm-CS (DS = 0.5)
after 7 days immersion in vitro at 37°C. (A) Low CS Content, 2000:1 NIPAAm:CS molar
ratio. (B) High CS Content, 600:1 NIPAAm:CS molar ratio.
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Figure 7.3 Human mesenchymal stem cells (hMSC, P.6) in culture prior to seeding
within PNIPAAm-CS scaffolds.
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A. Day 14 10x Magnification, PNIPAAm-CS

B. Day 21 10x Magnification, PNIPAAm-CS

C. Day 21 10x Magnification, PNIPAAm

Figure 7.4 Comparison between hMSC viability within PNIPAAm-CS copolymer (600:1
NIPAAm to CS molar ratio, DS = 0.5) and PNIPAAm homopolymer. (A) 14 days
incubation in PNIPAAm-CS; (B) 21 days incubation in PNIPAAm-CS; (C) 21 days
incubation in PNIPAAm homopolymer control. Images at 10x phase objective; scale
bars represent 100 µm.
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Chapter 8
Conclusions and Future Recommendations
8.1 Conclusions
Tissue engineering is a multidisciplinary field that aims to develop biological
materials for functional restoration or regeneration of damaged and defective tissues (64,
79).

The overarching goal of this work was to develop and characterize poly(N-

isopropylacrylamide)-based scaffolds for the repair of injured spinal cord tissue and the
regeneration of nucleus pulposus tissue in early stage intervertebral disc degeneration.
In the first aim, poly(N-isopropylacrylamide) was grafted with polyethylene
glycol, using established methods, to yield a synthetic copolymer hydrogel for
application in spinal cord injuries. Given that the success of any biomaterial relies
heavily on cell-scaffold interactions, the biocompatibility of PNIPAAm-PEG was
investigated in vitro using two clinically relevant cells lines. The lower critical solution
temperature of the scaffold was exploited to uniformly distribute the cells throughout the
matrix prior to the solution-to-gel phase transition. In this manner, human embryonic
kidney cells (HEK) were seeded within PNIPAAm-PEG and cultured in vitro at 37°C
over 25 days. By using a qualitative dual fluorescent LIVE/DEAD stain to detect viable
and non-viable cells, HEK were shown to both survive and proliferate throughout the
scaffold.

These results were confirmed in a quantitative assay that measured the

mitochondrial activity of the cells through conversion of a tetrazolium dye into an
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insoluble formazan, which is subsequently solubilized and detected by the optical density
at 562 nm.

The absorbance measurements revealed an increase in HEK activity

throughout 18 days of in vitro culture with PNIPAAm-PEG at 37°C, further
demonstrating the cytocompatibility of the scaffold. In addition to HEK, rat fibroblasts
expressing green fluorescent protein were cultured within PNIPAAm-PEG over 15 days,
and subsequently fixed and imaged by fluorescence microscopy.

As expected, this

qualitative study revealed an increase in GFP expression attributed to fibroblast viability
and proliferation.

Despite observations of unattached cell morphologies, these data

indicate that PNIPAAm-PEG exhibits suitable biocompatibility in vitro. To summarize,
PNIPAAm-PEG is a candidate scaffold to serve as a minimally invasive, space-filling
substrate for the local delivery of cells and growth factors to tissue defects, and has
potential to facilitate and promote neuronal survival and axon regeneration following
injury to spinal cord tissue.
In the second aim, a novel PNIPAAm-based copolymer was synthesized by
incorporating chondroitin sulfate, a glycosaminoglycan and constituent of nucleus
pulposus tissue, along the backbone of PNIPAAm to yield a biodegradable scaffold for
application in intervertebral disc degeneration.

Using reported methods, CS was

functionalized with methacrylate groups and success of the substitution was verified
using

1

H NMR spectroscopy.

Thereafter, free radical polymerization of N-

isopropylacrylamide and methacrylate-substituted CS was achieved using APS and
TEMED as the initiator and accelerator, respectively. As a result, a family of PNIPAAmCS copolymers was produced with varying degrees of methacrylate substitution on CS
and varying molar ratios of synthetic to natural polymer chains. Purification of the
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copolymers at 37°C not only demonstrated the thermoresponsive properties of the
hydrogels, but also revealed apparent differences in swelling behavior as a function of CS
concentration. Although 1H NMR did not sufficiently confirm the relative PNIPAAm
and CS concentrations, it verified the removal of unreacted monomer and macromer from
the network during purification. PNIPAAm-CS copolymers that formed adequately solid
gels in this aim were selected for further characterization.
Consequently, the effects of copolymer composition and degree of methacrylate
substitution on the swelling and mechanical properties of the PNIPAAm-CS were
explored in the third aim. By measuring the dry mass of the hydrogels after 14 days of
immersion in PBS at 37°C, the equilibrium water content of the copolymers was shown
to increase as the amount of CS increased and degree of methacrylate substitution
decreased. These results correlated well with the moduli of the hydrogels obtained from
unconfined compression testing after 14 days of immersion in PBS.

As expected,

decreasing the molar ratio of NIPAAm to methacrylate-substituted CS facilitated
hydrogel swelling due to the negatively charged carboxyl and sulfate radicals on CS that
attract water; as a result, these copolymers also exhibited higher elasticity. Likewise,
increasing the degree of substitution on CS increased the physical entanglements and
interactions between the chains of PNIPAAm-CS, inhibiting its ability to swell and retain
water; hence, these copolymers exhibited higher stiffness.

Notably, the mechanical

properties of these hydrogels were consistent with those reported in literature using
similar polymers and are comparable to that of native nucleus pulposus tissue.

In

general, these data demonstrate that PNIPAAm-CS hydrogels can be tailored in order to
mimic the properties of native nucleus pulposus tissue.
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Finally, the biodegradability and cytocompatibility of selected PNIPAAm-CS
scaffolds were characterized in the last aim.

The initial and final dry masses of

copolymers with high and low CS content were compared over 7 days of in vitro
immersion in chondroitinase ABC, an enzyme that acts on glycosaminoglycans. As
expected, PNIPAAm-CS copolymers with high concentrations of degradable chondroitin
sulfate exhibited significant mass losses relative to those containing low CS content and
to control copolymers immersed in PBS without enzyme. These data not only prove that
PNIPAAm-CS copolymers are biodegradable, but also suggest that modifying the
hydrogel composition can control the rate of degradation. Given that the breakdown
products are natural constituents found in vivo, PNIPAAm-CS would not be expected to
elicit an adverse immune reaction as the temporary scaffold is replaced with regenerated
tissue. As a preliminary assessment of cell-scaffold interactions, human mesenchymal
stem cells, which can differentiate into the cartilage cells of nucleus pulposus tissue, were
seeded within PNIPAAm-CS and viability was qualitatively measured by reaction of a
non-fluorescent cell-tracing dye into a highly fluorescent label. The hMSC appeared to
survive and proliferate after 21 days in vitro, and demonstrated comparable
cytocompatibility to the PNIPAAm control.

In conclusion, PNIPAAm-CS is an

injectable and biodegradable thermoresponsive scaffolds that can be used as a temporary
support for cell survival and proliferation to repair the nucleus pulposus in early
intervertebral disc degeneration.
Overall, this work demonstrates that injectable and thermoresponsive poly(Nisopropylacrylamide)-based hydrogels are promising substrates for application in spinal
cord repair and nucleus pulposus regeneration.
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8.2 Recommendations for Future Work
The data presented in this work have exciting implications for tissue engineering
of the spinal cord and nucleus pulposus. In regard to PNIPAAm-PEG, future work
should be completed in vitro to more accurately predict cell-scaffold interactions in vivo.
Specifically, the ability of clinically relevant cells, like neuronal- and glial-restricted
precursors (NRP and GRP), to differentiate and produce tissue-specific molecules while
incorporated within PNIPAAm-PEG should be determined. This can be achieved using
Polymerase Chain Reaction (PCR) to identify changes in NRP and GRP gene expression
caused by PNIPAAm-PEG (2). In conjunction, immunohistochemistry can be used to
qualitatively assess and visualize the presence of proteins like neurofilaments, glial
fibrillary acid protein and 5-HT2A, which can be used to distinguish among neuronal,
astrocyte and oligodendrocyte differentiation, respectively.

Using this approach,

PNIPAAm-PEG would be immunostained and tissue-specific protein production by
differentiated NRP and GRP would be observed with fluorescence microscopy. To aid in
new tissue formation and induce axon growth, PNIPAAm-PEG should be loaded with
proteins like brain-derived neurotrophic factor and the release rate from the scaffold
should be characterized. Aside from these in vitro studies, ex vivo or in vivo work is
recommended to assess the ability of PNIPAAm-PEG scaffolds, seeded with cells and
growth factors, to facilitate tissue regeneration and integration into the matrix in a more
relevant model of spinal cord injury.

Such in vivo work has since been reported

following the completion of the studies presented here, and further demonstrate the
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potential of PNIPAAm-PEG as an injectable, multifunctional scaffold for repair of spinal
cord tissue (78).
Regarding PNIPAAm-CS scaffolds, the physical properties of these copolymers
should be further explored. First and foremost, the compositions of the copolymers need
to be confirmed using alternative methods to 1H NMR spectroscopy, including but not
limited to Fourier Transform Infrared Spectroscopy or colorimetric assays that
specifically bind to chondroitin sulfate, such as dimethylmethylene blue. Although the
family of hydrogels tested appeared to exhibit phase transitions at or near physiological
temperature, the lower critical solution temperatures of these copolymers should be
quantified to confirm these observations. This thermal analysis can be accomplished
using differential scanning calorimetry (DSC), which provides information about the
melting and glass transitions of the network, as well as its crystallinity (2). Given that
two vertebral bodies united by an intervertebral disc can move in virtually any direction
(10), the mechanical testing presented here represents only a preliminary assessment of
its feasibility as a nucleus pulposus replacement.

In addition to quantifying the

compressive moduli of PNIPAAm-CS undergoing degradation, recommended studies for
future work include stress-relaxation and creep recovery experiments to evaluate the
elastic recovery and plastic deformation behavior of PNIPAAm-CS.

Since the

intervertebral discs are subjected to repeated loading, it is critical to characterize and
understand the fatigue behavior of PNIPAAm-CS as a potential weight-bearing nucleus
pulposus replacement.

Aside from the mechanical properties of PNIPAAm-CS, the

swelling and mass retention of the hydrogels should be confirmed over longer periods of
in vitro immersion in PBS and other physiologically relevant media.
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As described above, the cell-scaffold interactions should be well understood in
vitro; however, the bioactivity of PNIPAAm-CS and its biological response was not
evaluated in detail in this work.

Using the same approach as PNIPAAm-PEG,

differentiation of human mesenchymal stem cells into chondrocytes, a major constituent
of nucleus pulposus tissue, should be tested after incorporation into PNIPAAm-CS.
Likewise, the presence of tissue-specific proteins and markers should be confirmed to
assess the potential for nucleus pulposus regeneration. New tissue formation can also be
promoted by incorporating growth factors into the scaffold (112). Finally, due to the fact
that migration is a major cause of implant failure, an assessment of the bioadhesive
properties of PNIPAAm-CS is warranted; consequently, following the completion of this
work, such studies have been initiated and are ongoing (113).
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